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Diffuse intrinsic pontine glioma (DIPG) is an incurable pediatric brainstem tumor.  
Genomic studies of autopsy and biopsy tissue revealed the presence of recurrent mutations in 
activing A receptor, type 1 (ACVR1) and lysine to methionine mutations at position 27 (K27M) 
in the genes encoding histone H3 variants, H3.1 and H3.3. To study the role of the mutations on 
DIPG tumorigenesis we developed genetically engineered brainstem glioma models harboring 
recurrent DIPG mutations, ACVR1 G328V and histone H3.1 K27M. Histological analysis 
indicates tumors generated were diffuse and localized in the brainstem. Survival analysis 
demonstrated that ACVR1 G328V enhanced median survival, while the H3.1 K27M mutation 
did not significantly affect median survival independently of ACVR1 G328V.  We also 
developed a transplantable model of DIPG by implanting mutant ACVR1 tumor neurospheres 
into the pons of immune competent mice. This enabled us to test the therapeutic efficacy and 
toxicity of immune stimulatory gene therapy using adenoviruses expressing thymidine kinase 
(TK) and fms-like tyrosine kinase 3 ligand (Flt3L). Our results show that adenoviral delivery of 
TK/Flt3L in mice bearing mutant ACVR1 brainstem glioma resulted in anti-tumor immunity, 
recruitment of anti-tumor specific T cells and increased median survival.  Histopathological 
analysis shows that TK/Flt3L was well tolerated in the brainstem. The results from this thesis 
work provide support for continued clinical investigation into TK/Flt3L immune stimulatory 
gene therapy for DIP. 
 1 
Chapter 1: Introduction1 
Clinical aspects of DIPG 
Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive pediatric brain cancer that 
is currently incurable. DIPG occurs in children of median age of 6-7 years and bears a bleak 
prognosis: a median survival of 11 months with only 10% of DIPG patients surviving two years 
from onset (1). A DIPG diagnosis results from the culmination of acute neuropathological 
symptoms including cranial nerve palsies, long-tract and cerebellar signs, in addition to the 
characteristic radiographic abnormality in the pons (1). The longstanding standard treatment for 
DIPG is focal radiation (2). Radiation provides mitigation of symptoms and slows down tumor 
growth in the majority of DIPG patients (3,4). Unfortunately, the efficacy of radiotherapy is 
limited and provides only transient symptomatic relief and meager benefits to DIPG patient 
survival (4-7). Numerous clinical trials have evaluated other treatments (alone and in 
combination with radiation) such as cytotoxic chemotherapy, small molecule inhibitors, and 
immunotherapies. However, none of these therapies have demonstrated a significant 
improvement in patient survival without imposing substantial adverse side effects (7).  
 The location of DIPG tumors poses a challenge for diagnosis and treatment. DIPG tumors 
infiltrate the pons, a region of the brainstem that regulates basic functions like breathing, blood 
 
1 Portions of this chapter have been published in: Mendez, F.M., Nunez, F.J., Garcia-Fabiani, M.B., Haase S., 
Carney, S., Gauss, J.C., Becher, O.J., Lowenstein, P.R., and Castro, M.G. Epigenetic reprogramming and chromatin 
accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease, Neuro-Oncology, 2019, 
noz218. 
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pressure, and heart rate. The crucial functions of the pons and the inability to differentiate tumor 
cells from normal tissue in the operating room makes surgical resection impossible. Even a 
biopsy of the tumor was felt to be unnecessary given that the results would not change clinical 
management. Contemporary practice still relies on the characteristic MRI abnormality of these 
tumors to confirm a DIPG diagnosis: a T2 hyperintense signal abnormality occupying at least 
50% of the pons (8). This general practice will likely continue until molecular and pathological 
evaluation of DIPG tumors is able to meaningfully impact the standard of care. Nevertheless, 
biopsy remains a significant aspect of DIPG management, as the scarcity of DIPG samples poses 
challenges to the characterization and development of novel therapeutic agents for this disease. 
Progress has been made recently with numerous studies reporting on the safety and low 
morbidity of computer-aided stereotactic biopsies since their development in 1978 (9-12). There 
is also evidence suggesting that liquid biopsies, utilizing cerebral spinal fluid or plasma, 
represent a promising future strategy to diagnose and monitor DIPG via the distinct markers 
present on the circulating tumor DNA (13). While the dire need to improve DIPG treatment 
remains, the increase in biopsy has facilitated significant advances in determining the hallmark 
genetic characteristics of DIPG—namely the 2012 discovery of H3K27M mutations in 
approximately 85% of DIPG tumors (14,15). Biopsies are now being increasingly performed at 
academic medical centers in order to designate patients into genetically stratified clinical trials, 
with the hope that such targeted treatments will provide improvements in DIPG treatment(16). 
 Pathological evaluation of DIPG describes a diffuse tumor of the pons, often infiltrating 
the of medulla and midbrain, with otherwise typical characteristics of histopathological 
heterogenous glial neoplasms (17). Historically, high-grade glioma was defined by the World 
Health Organization (WHO) based on histopathological characteristics such as the presence of 
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microvascular proliferation or necrosis. However, the most recent WHO classification of central 
nervous system tumors, published in 2016, began incorporating molecular testing as part of its 
diagnostic criteria. This led the WHO to define a new neoplastic entity establishing midline 
gliomas (e.g., brainstem, thalamic, spinal cord) harboring H3K27M mutations and diffuse 
growth as “diffuse midline gliomas, H3K27M-mutant” (18). This term includes 80% of DIPGs 
harboring H3K27M mutations (14,15,19). Herein, we refer to mutations of lysine 27 to 
methionine as H3K27M, due to the nomenclature used in the original reports. However, based on 
standard mutation nomenclature it is lysine 28 that is mutated to methionine (20). 
Normal postnatal development of the human and murine pons 
Our understanding of DIPG may be enhanced by studying the postnatal development of 
the human pons. A morphometric analysis of the human pons 0-18 years of age found that there 
is a rapid, sixfold increase in the volume of the pons from birth to age five, followed by slower 
but continued growth throughout childhood (21). MRI and histological analysis of myelin basic 
protein indicate that this expansion of the pons is likely due to an increase of myelination in the 
basis pontis (21). Ki67 staining also revealed that the number of proliferative cells began to 
decline rapidly from 0-7 months followed by a further decline by age 3, and only a small 
population persisted throughout childhood (21). Two populations of vimentin/nestin-expressing 
cells were also identified — a dorsal group near the ventricular surface that persists throughout 
childhood, and a parenchymal population that declines by 7 months (21). Monje et al., utilized 
24 normal postmortem brainstem samples and analyzed neural precursor cells in the midbrain, 
pons, and medulla. They identified a nestin positive population in the ventral pons that peaks 
first during infancy, and then peaks for a second time at age 6 (22). The results from these 
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studies indicate that the human pons is undergoing continuous growth during childhood. It is 
noteworthy that two independent studies one using pons volume as a metric and the other using 
density of nestin-positive cells as a metric, suggest that there is a peak growth at approximately 5 
or 6 years of age, which correlates with age of incidence of DIPG. A murine study also observed 
a fivefold increase in the basis pontis postnatally, while the tegmentum grew fourfold (23). 
However, this rapid growth is not due to myelination as in the human pons, but is reportedly due 
to proliferation (23). The pons is the most proliferative brainstem region in comparison to the 
midbrain or medulla (23). A parenchymal progenitor population of sex-determining region Y-
box 2 (Sox2+), oligodendrocyte transcription factor 2 (Olig2+) was identified as the main 
proliferative progenitor population, and Lindquist et al., also found that the majority of adult 
pons oligodendrocytes were found to be derived from postnatal Sox2+ progenitors (23). Overall, 
the murine pons growth postnatally resembles human pons growth. Lineage tracing studies using 
markers of progenitor cell populations could help increase our understanding of the cell of origin 
of DIPG.  
Cell of origin in DIPG 
If DIPG originates from a postnatal cell then the cell of origin in DIPG may be the 
proliferative Ki67+/Olig2+ proliferative population identified by Tate. et al., in the postnatal 
pons, or the nestin+ population identified by Monje and colleagues (21,22). The hypothesis that 
DIPG arises from a postnatal precursor cell is supported by the findings of Funato et al., 
demonstrating that the H3.3 K27M mutation, together with platelet derived growth factor 
receptor A (PDGFRA) activation and p53 loss, was sufficient to induce neoplastic 
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transformation in human embryonic stem cells (ESCs) and that expression of H3.3 K27M led to 
a resetting of neural precursors to a more primitive stem cell state (24).  
However, it is also possible that the cell of origin is an embryonic precursor cell. Pathania 
et al., performed in utero electroporation to over express H3.3 K27M in neural progenitor cells in 
the lower rhombic lip of the developing hindbrain where some pontine nuclei are derived. They 
found that in combination with Trp53 loss it was sufficient to induce both focal and diffuse 
tumors, but expression of H3.3 K27M postnatally did not yield the same results (25). Sun et al., 
also demonstrated that the H3.3 K27M mutation was sufficient to immortalize human fetal 
hindbrain-derived neural progenitor cells, but not cortex derived progenitor cells (26). This 
finding suggested that only human fetal hindbrain-derived neural progenitor cells could become 
oncogenic with the introduction of the highly prevalent H3.3 K27M mutation.  
 In support of a developmental origin, whether postnatal or prenatal, single cell RNA 
sequencing of six H3 K27M mutated glioma patients identified that they have a developmental 
hierarchy, with some tumor cells having transcriptional profiles that were associated with either 
astrocytic differentiation, oligodendrocytic differentiation, and oligodendrocytic progenitor-like 
programs (27) .This study also revealed that the largest fraction of stem-like cells in DIPGs were 
oligodendrocyte progenitor-like cells (OPCs), supporting the hypothesis of a precursor OPC cell 
of origin for DIPG (27). 
Genetic mutations in DIPG 
The developmental regulator activin A receptor type 1 (ACVR1) is a frequently mutated 
gene in DIPG present in approximately 24% of patients(28). There are six somatic mutations 
occurring in either the glycine serine rich domain or the kinase domain (Figure 1.1) (29-32). The 
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most frequent mutation is the G328V mutation, which we model in Chapter 2. ACVR1 mutations 
are typically observed in younger DIPG patients(29-32). ACVR1 has been shown to be 
necessary to establish proper patterning in late gastrulation during embryogenesis for normal 
craniofacial and cardiac development (33-35). The receptor is part of the transforming growth  
factor beta (TGF-β) family. Normally, upon bone morphogenetic protein (BMP) ligand binding, 
type 2 BMP receptor kinase phosphorylates ACVR1, a type 1 BMP receptor. This initiates a 
downstream signaling cascade through phosphorylation of the Smad transcription factors (Figure 
1.2)(36). However, ACVR1 mutations result in ligand independent activation of the Smad1/5/8 
signaling pathway(29-32,37).  
Canonically, ACVR1 phosphorylates Smad1/5/8 (38). ACVR1 is also mutated in the 
congenital disorder fibrodysplasia ossificans progressive (FOP) (39). Interestingly, cells 
expressing mutated ACVR1 respond to activin ligands to which wild-type ACVR1 does not 
normally respond (40,41). In models of FOP, activin-ACVR1 signaling was sufficient to induce 
heterotypic ossification (40,41). DIPG cells harboring mutated ACVR1 have also been shown to 
 
Figure 1.1 ACVR1 mutations in DIPG 
A schematic of ACVR1 domain organization showing the position of mutations that have been 
described in DIPG. Mutations labeled with an asterisk have also been described to occur in 
patients with FOP. The ligand binding (LD), glycine serine rich (GS), and kinase domain are 
labelled.  
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exhibit an aberrant response to activin A (42). Activin receptor signaling  regulates 
oligodendrocyte lineage cell responses during white matter development and after injury(43).  
During development, BMPs are tightly regulated temporally and spatially by other 
signaling pathways (36). Postnatally, BMPs promote astrogliogenesis while inhibiting both 
neurogenesis and oligodendrogliogenesis (36). Although a lot is known about BMP signaling in 
the brain, the role of BMP signaling or ACVR1 has not been studied in the early postnatal pons. 
Identifying the implications of ACVR1 or other BMP interacting/inhibitory pathways on neural 
 
Figure 1.2 ACVR1 signaling pathway 
A cartoon of the ACVR1 signaling pathway. ACVR1 is a type I BMP receptor which forms a 
heteromeric complex with type II BMP receptors upon BMP ligand binding. Activated ACVR1 
then phosphorylates the Smad1/5/8 transcription factors.  Phosphorylated Smad1/5/8 
transcription factors are then able to bind to Smad 4 and translocate into the nucleus to regulate 
transcription. An asterisk represents the ACVR1 G328V mutation which results in auto-
activation of this pathway independent of BMP ligand binding.  
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precursor or proliferative populations could provide new directions for development of therapies.  
In addition to activating ACVR1 mutations, there have also been amplifications in inhibitor of 
DNA binding protein 2 (ID2), ID3, mutations in BMP3, BMPK, and others in approximately 
19% of DIPG, underscoring the importance of the BMP pathway in DIPG (44). Hoeman et al., 
found that in vitro expression of ACVR1 R206H upregulated mesenchymal markers and 
activated signaling of signal transducer and activator of transcription 3 (Stat3) (45). Using a 
replication-competent avian sarcoma-leukosis virus long terminal repeat splice acceptor (RCAS) 
mouse model with PDGFA, the authors also found that ACVR1 R206H accelerated 
gliomagenesis and cooperates with H3.1 K27M to accelerate tumor growth and malignancy (30). 
In vivo inhibition of ACVR1 with the LDN212854 inhibitor also significantly increased median 
survival in the RCAS model described above (45).  In addition, treatment with ACVR1 
inhibitors, LDN-139189 and LDN-214117, prolonged survival in orthotropic patient-derived 
xenograft models of ACVR1 R206H (42).  Thus, ACVR1 may be an important therapeutic target 
for the treatment of DIPG.  
TP53, the gene encoding the tumor suppressor p53, is mutated in 42% of DIPG tumors. 
Survival and apoptosis in the developing and adult nervous systems are regulated by p53 (29,46). 
In the brain, p53 is preferentially expressed in progenitor cells, and in vitro experiments using 
neurospheres (NS) from p53 null mice suggested that TP53 regulates cell cycle progression and 
apoptosis (47,48). An increased proliferation rate in neural stem cells could make them 
susceptible to acquiring additional mutations that lead to malignancy.  
Protein phosphatase, Mg2+/Mn2+-dependent 1D (PPMI1D), mutated in 23% of DIPG 
cases, is expressed in the fetal mouse brain and germline mutations of PPM1D lead to an 
intellectual disability syndrome, suggesting a role in neurodevelopment (31). PPM1D 
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dephosphorylates the DNA damage response proteins p53, checkpoint kinase 2, ataxia 
telangiectasia mutated, and, gamma-H2A histone family member X to enable re-entry into the cell 
cycle following cellular stress (49). PPMI1D plays a critical role in central nervous system 
homeostasis by regulating G2/M cell cycle progression in adult neural progenitor cells through 
inhibition of p53 activity (50). Thus, PPM1D and p53 together modulate the balance between 
self-renewal of neural progenitor cells while minimizing genotoxic stress. In DIPG, truncating 
mutations of PPM1D that stabilize the protein are mutually exclusive with TP53 mutations 
(31,51).  
   DIPGs are also characterized by amplifications of genes that regulate the G1-S cell cycle 
progression, particularly cyclin D family members CCND1, CCND2, CCND3 and cyclin 
dependent kinase inhibitors CDK4 and CDK6 (31,52,53). Cyclins and cyclin dependent kinases 
form a complex that phosphorylates retinoblastoma protein, allowing for cell cycle progression 
(54). The regulation of the cell cycle progression and length is important for neurogenesis. In 
vitro, neural precursor cells with dominant negative forms of CDK2, CDK4, and CDK6 undergo 
cell cycle arrest (55).  The overexpression of cyclin D and CDK4 in neural progenitors of 
developing brain shortened G1 length and inhibited neurogenesis demonstrating that a 
lengthening of G1 regulates the switch from proliferation to neurogenesis (56).  Uncontrolled 
proliferation is a characteristic of many cancers, and there are currently four clinical trials testing 
the efficacy of CDK4/6 inhibitors that were initially developed for other cancers in DIPG 
(NCT02255461, NCT03387020, NCT03355794, NCT02644460). The results of these clinical 
trials will shed light on the effectiveness of CDK4/6 inhibitors as a single therapeutic agent in 
DIPG.  
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The most frequent mutation in DIPG is a K27M mutation that occurs on genes encoding 
histone H3 variants H3.3 and H3.1/2 (14,15,19). Histones are proteins that package DNA into 
compact units called nucleosomes, an octamer comprised of four core histones (H2A, H2B, H3, 
and H4) and approximately 147 base pairs of DNA (57). Nucleosome cores are connected by a 
strand of linker DNA that is stabilized by the recognition and binding of histone H1 (57). 
Histone H3 is post-translationally modified (methylation, acetylation, ubiquitiniation, 
sumoylation, etc.) on the N-terminal tail to regulate transcription, DNA replication and repair. 
H3.1 and H3.2 are canonical histones encoded by multiple genes which are “replication-
coupled,” meaning that they are synthesized and deposited on DNA during S-phase (Table 1.1) 
(57). The histone variant H3.3 is a non-canonical histone (Table 1.1). Non-canonical histones, in 




 Histone variants have distinct functions—for example H3.3. is typically deposited on 
transcriptionally active genes and generally harbors post-translational modifications associated 
with activation. Meanwhile H3.1 and H3.2 are associated with inactivation modifications (58). 
An analysis of histone H3 gene expression in silico during human brain development found that 
genes encoding the H3.3 variant, including H3F3A, were present at all developmental stages; 
however, their expression did gradually decrease across developmental stages (59). In contrast, 
the genes encoding the H3.1 variant, including HIST1H3B are silenced at early developmental 
stages (59). One important caveat that the authors noted was that H3.1 transcripts lack 
 
Table 1-1: Summary of histone H3 variants 
Table listing genes encoding for canonical and non-canonical histone H3 variants. Despite 
many genes encoding for canonical histone H3 variants H3.1 and H3.2 only the HIST1H3B, 
HIST1H3C, and HIST2H3C genes have been observed to be mutated in DIPG. Three genes 
encode for the H3.3 variant, but only the H3F3FA gene is mutated in DIPG.  
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polyadenylation and thus are potentially underrepresented in poly(A)-derived cDNA libraries 
and RNA-seq data sets used in the study (59).  
Polycomb Repressive Complex 2 (PRC2), is a Polycomb group (PcG) protein, which is 
composed of three core subunits enhancer of zeste homolog 1 (EZH1) or EZH2, embryonic 
ectoderm development (EED), and suppressor of zeste 12 homolog (SUZ12)—that mediates the 
repression of developmental genes (60). EZH1 and EZH2 contain a conserved catalytic 
Su(var)3-9/enhancer-of-zeste/trithorax (SET) domain found in many lysine methyl transferases, 
which catalyzes the di-, and tri-methylation of histone 3 lysine 27 (H3K27me2/3) (61). 
H3K27me3 is a repressive mark that is associated with inactive gene promoters (60). The 
trithorax group of proteins, on the other hand, are antagonistic regulators of  PcG proteins and 
include the SET1 family  (SET1A, SET1B, MLL1, MLL2, MLL3, and MLL4 in humans), which 
catalyze  methylation of histone 3 lysine 4 (62). Tri-methylation of histone 3 lysine 4 
(H3K4me3) is associated with active chromatin (62). In DIPG cells, the genomic distribution of 
H3K4me3 methylation is largely unaltered compared with neural stem cells (63). 
H3K27M  functions as a dominant negative mutation that dramatically reduces global 
levels of H3K27me3 in DIPG cells and tissue even though H3K27M protein makes up only a 
small percentage of total H3 (3-17%  in DIPG cells as measured by mass spectrometry )(63-65). 
Several hypotheses have been suggested to explain the mechanism of global reduction of 
H3K27me3 by the H3K27M mutation.  Lewis et al., observed that synthetic H3K27M peptides 
interact with the EZH2 active site (64). In support of this, co-immunoprecipitation by 
experiments of wild-type or H3.3 K27M containing mono-nucleosomes revealed enrichment of 
EZH2 and SUZ12 proteins in mutated nucleosomes (65). Bender et al., also demonstrated that 
the H3.3 K27M mutation decreased EZH2 methyltranferase enzymatic activity (65).  
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Additionally, a biochemical study demonstrated that EZH2 recognizes the histone H3 tail (66). 
The authors also showed that inhibition of EZH2 catalytic activity by H3K27M could be 
alleviated through enhanced acetylation of surrounding chromatin regions (66). Consistent with 
this, a crystal structure of the human PRC2 complex with the H3K27M peptide demonstrated 
that the mutant peptide binds to the active site of the SET domain.  Furthermore, the binding of 
EED to H3K27me3, present as a result of an existing repressive mark, leads to the stabilization 
of the SET domain. This enhances the binding of PRC2 with the H3K27M peptide (67). The 
resulting theories suggest that H3K27M binds to the EZH2 component of the PRC2 complex, to 
inactivate or sequester the complex, thus preventing it from carrying it out di- and tri-
methylation on wild-type nucleosomes (Figure 1.3 A).  
 However, Piunti, A. et al., reported that EZH2 and SUZ12 are largely excluded from 
chromatin containing H3.3 K27M. Instead mutant K27M proteins are found in regions that 
contain H3K27 acetylation, which many groups had reported to be increased in H3.3 K27M 
mutant cells (64,68,69). Subsequently, they found that PRC2 activity is required for DIPG cell 
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2maintenance and growth through potentially dependent or independent repression of p16, a 
 
2 This figure was originally published in: Mendez, F.M., Nunez, F.J., Garcia-Fabiani, M.B., Haase S., Carney, S., 
Gauss, J.C., Becher, O.J., Lowenstein, P.R., and Castro, M.G. Epigenetic reprogramming and chromatin 
accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease, Neuro-Oncology, 2019, 
noz218. 
 
Figure 1.3 Mechanisms by which H3K27M leads to defective PRC2 activity and global 
hypomethylation. 
(A) H3K27M mutatant histone inhibits (shown by curved bracket) the catalytic activity of 
EZH2 to deposit the H3K27me3 mark (shown by red arrow). (B) PRC2 is sequestered at poised 
enhancers b binding to H3K27M, which restrains the available PRC2 pool from binding to its 
strong affinity sites. (C) H3K27M interferes (shown by curved bracket) with the spread of the 
H3K27me3 mark by PRC2 (shown by black arrows) leading to global hypomethylation and 
transcriptional de-repression.  
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PRC2 target gene (68).  Indeed, others have observed locus specific enrichment of H3K27me3 in 
H3K27M  expressing cells, and hypothesize that H3K27M promotes tumorigenesis through 
repression of tumor suppressors (63).  In support of this, using a genetic mouse model, Cordero 
et al., found that the H3.3 K27M mutation in the context of PDGF signaling promoted 
gliomagenesis through repression of the p16 tumor suppressor (70). Additionally, a mouse model 
generated by neonatal induction of H3.3 K27M, PDGFRA, and Trp53 demonstrated that H3.3 
K27M accelerated tumor development, and that genes enriched in H3.3 K27M tumors were 
associated with bivalently regulated neural developmental genes (71). Silveira et al., observed 
that knockdown of H3F3A, the gene encoding the H3K27M mutation, restored H3K27me3 
levels (72). The restoration of this repressive mark resulted in a promoter shift from active to 
bivalent state in 32-48% of genes upregulated by K27M(72).  Similarly, a study using embryonic 
stem cells expressing the H3.3 K27me3 mutation found that EZH2 (a component of PRC2) is 
sequestered to poised enhancers, which was unique to H3K27M-expressing cells compared with 
wild-type H3.3 ESCs. The authors propose that the limited availability of PRC2 to bind its strong 
affinity sites across the genome leads to global hypomethylation (Figure 1.3 B). The authors also 
found that H3K27M is enriched at highly transcribed genes and is low within regions that are 
enriched in H3K27me3 peaks, thereby allowing for H3K27me3 silencing at those sites. 
Recently, Harutyunyan et al., have reported that the global deposition of H3K27me2/3 is reduced 
in H3.3 K27M cells and that removal of H3K27M could rescue this effect (73). These findings 
suggest that neither the recruitment of PRC2 nor its ability to deposit H3K27me3 in the local 
proximity of unmethylated cytosine-phosphate-guanine (CpG) islands is affected by H3K27M. 
Instead the ability of PRC2 to facilitate the spread of the H3K27me3 mark is inhibited by 
H3K27M, represented by the reduced distribution of H3K27me3 at these sites (Figure 1.3 C) 
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(73). Interestingly, posterior fossa type A ependymomas with high expression of enhancer of 
zeste homolog inhibitory protein (EXHIP) are also characterized by global loss of H3K27me3 
and retention of this mark at CpG islands (74-76). Several groups have recently reported that a 
conserved sequence in EZHIP functions as an endogenous H3K27M analog that inhibits PRC2 
activity (76-78). Jain et al, propose a model where EZHIP blocks H3K27me3 spreading by 
inhibiting allosterically-activated PRC2 (76). Thus, the K27M mutation and EZHIP appear to 
deregulate PRC2 activity by similar mechanisms. In chapter 2, I describe the development of a 
mouse model with the ACVR1 G328V and H3.1 K27 mutations that enabled us to study the 
function of these mutations in DIPG tumorigenesis. 
Immunotherapy 
The dismal prognosis of DIPG requires the development of novel treatment approaches. 
Immunotherapy, an approach that uses the body’s immune system to fight cancer has grown 
immensely.  Several immunotherapies have been approved by the Food and Drug Administration 
(FDA) including a dendritic cell vaccine for prostate cancer, and pembrolizumab, a monoclonal 
antibody for the PD-1 receptor, an immune checkpoint protein, which received approval for the 
treatment of unresectable or metastatic solid tumors with high microsatellite instability or 
mismatch repair deficiency(79-81). These successes in solid tumors have yielded much interest 
in the use of immunotherapies for the treatment of brain tumors.    
Nevertheless, there are several features of high-grade gliomas that need to considered for 
the successful implementation of immunotherapeutic strategies.  For example, some of the most 
promising immunotherapies are immune checkpoint blockade drugs.  Immune checkpoint 
blockade drugs are based on the use of monoclonal antibodies that block inhibitory signals of T 
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cell activation (82). However, the efficacy of immune checkpoint inhibitors is thought to 
correlate with mutational burden, and both adult glioblastoma and DIPG tumors have a low 
mutational burden (83,84). Despite the proposed correlation, there are some patients with low 
tumor burden that benefit from immune checkpoint blockade drug, and there are currently a 
number of ongoing clinical trials testing the safety and efficacy of these drugs in DIPG (85-88).  
Another feature of gliomas is high tumor heterogeneity which is a problem for single targeted 
immunotherapies such as peptide vaccines targeting specific tumor antigens, since high 
heterogeneity can lead to antigen escape (89,90).  
The unique environment of the brain also poses a challenge.  The brain has a functional 
lymphatic system, and there is evidence of immunosurveillance within the brain and T cell 
entry(91,92). However, in comparison to peripheral organs, the brain has few resident 
professional antigen presenting cells (APCs) (93). The presentation of antigen to T cells by 
APCs is essential for the activation of the adaptive immune response (94). Perhaps not 
surprisingly, glioblastomas have few infiltrating immune cells (95).  The glioma 
microenvironment also has high levels of immunosuppressive cytokines such as TGF-β and IL-
10 (96,97). At late stages of glioma, TGF-β promotes the expansion of regulatory T cells (96,97). 
Meanwhile, IL-10 has been shown to inhibit the activation and effector function of T cells, 
monocytes, and macrophages (97,98). In addition, IL-10 also downregulates MHC class II 
expression on monocytes, and inhibits anti-tumor immune responses by inhibiting production of 
interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) by immune cells (97,99). 
Gliomas also promote the expansion of an immunosuppressive network of immune cells such as 
myeloid-derived suppressor cells (MDSCs), tumor associated macrophages/microglia (TAMs), 
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and regulatory T cells (Tregs) which further prevent gliomas from initiating an effective 
antitumor immune response (96).    
DIPG tumor microenvironment 
The DIPG microenvironment has not been as extensively studied as that of adult gliomas 
has.  One recent study compared the tumor immune microenvironment of DIPG with adult 
glioblastoma tumors found that DIPG tumors had less infiltrating T cells (100). Using tissue 
microarrays a second study found that, compared to control adjacent brain tissue, DIPG samples 
did not have extensive TAMs, nor increased T cell infiltration (101). In addition, macrophages 
from DIPG tumors expressed fewer inflammatory factors compared to macrophages from adult 
glioblastoma tumors, including lower levels of IL6, IL1A, IL1B, CCL3, CCL4, among other 
inflammatory factors (100). DIPG tumor cells also secreted fewer cytokines and chemokines 
compared to GBM tumor cells (100,101). Overall, initial studies of the DIPG tumor immune 
microenvironment suggest that DIPG tumors are unable to initiate effective anti-tumor immune 
responses. In addition, it appears that DIPGs do not have the immunosuppressive factors that 
characterize adult gliomas, therefore immunotherapies that improve the recruitment of cytotoxic 
lymphocytes may be especially effective since they may not need to overcome an 
immunosuppressive tumor microenvironment (101). 
Immune stimulatory gene therapy  
Our laboratory has successfully employed a strategy based on increasing dendritic cell 
infiltration into the tumor microenvironment (102-107).  Dendritic cells are the most efficient 
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antigen presenting cells (102,108). They take up antigens, process them and load them onto 
major histocompatibility complex (MHC) class I and II molecules. Dendritic cells then migrate 
to the draining lymph nodes and present antigens to T cells, initiating antigen-specific immune 
responses (94).  Our strategy to enhance anti-tumor immune responses relies on the adenoviral 
delivery of two genes, a conditionally cytotoxic gene, thymidine kinase, and Flt3L. Flt3L, is a 
growth factor that induces dendritic cell differentiation, proliferation, and activation (102,109). 
TK phosphorylates the prodrug ganciclovir (GCV) to GCV-monophosphate. Cellular kinases 
convert it into GCV triphosphate which inhibits DNA polymerase causing DNA chain 
termination (110,111). Several phase I clinical trials have demonstrated that adenoviral 
administration of thymidine kinase is safe, although higher doses do cause neurotoxicity(112-
115). A phase III randomized control clinical trial in Europe demonstrated that adenoviral 
delivery of TK followed by intervenes GCV was safe and prolonged time to death, however it 
did not improve overall survival (116).  
Thus, our laboratory has used a combination therapy of adenoviral delivery of Ad-TK 
and Ad-Flt3L (Figure 1.4). This strategy relies on Ad-TK/GCV to induce tumor cell death while 
the delivery of Ad-Flt3L results in the recruitment of dendritic cells into the tumor 
microenvironment (106,117).  Cell death results in the release of tumor antigens and damage 
associated molecular pattern molecules which trigger an immune response against self-antigens 
(111). Indeed, we previously demonstrated that dying tumor cells release high-mobility group 
box 1 (HMGB1), into the tumor microenvironment, an endogenous toll-like receptor 2 (TLR2) 
ligand (106,107). Toll-like receptors (TLRs), are pattern recognition receptors that recognize 
patterns expressed by pathogens and DAMPs and stimulate dendritic cell activation(118). 
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HMGB1 activated dendritic cells then travel to the draining lymph nodes where they prime T 
cells to elicit an antigen specific cytotoxic immune response (106,107).  
Our laboratory has demonstrated that the combination of Ad-TK/Ad-Flt3L results in 
tumor regression, long term survival, and immunological memory in mouse and rat models of 
adult glioblastoma (103,104,119).  This combination therapy is currently being investigated in a 
Phase 1 clinical trial at the University of Michigan [NCT01811992] (120). We hypothesize 
that this therapy will also be effective for the treatment of DIPG, a tumor characterized by low 
immune cell infiltration. However, DIPGs are biologically very different tumors from adult 
gliomas. In chapter 3 of this thesis, I present evidence suggesting that this therapy is safe and 
effective in mouse model of brainstem glioma harboring the ACVR1 DIPG mutation.  
Summary 
DIPG is a rare pediatric brainstem tumor for which there is no treatment. Alterations in 
developmental and epigenetic mechanisms drive disease progression in DIPG. It is likely that 
DIPGs arise from an NPC that accumulates characteristic mutations. It is thought that the histone 
H3K27M mutation serves as the initial event, making the transformed cells susceptible to 
acquiring TP53, ACVR1, and additional mutations. The goal of this thesis was to generate 
immune competent, genetically engineered mouse models of brainstem glioma to investigate the 
role of relevant DIPG mutations, and test the safety and effectiveness of immune stimulatory 




Figure 1.4 Diagram of adenoviral mediated TK/Flt3L gene therapy3
 
 
3 Image modified from David B. Altshuler, Padma Kadiyala, Felipe J. Nuñez, Fernando M. Nuñez, Stephen Carney, 
Mahmoud S. Alghamri, Maria B. Garcia-Fabiani, Antonela S. Asad, Alejandro J. Nicola Candia, Marianela 
Candolfi, Joerg Lahann, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein & Maria G. Castro. Prospects of 
biological and synthetic pharmacotherapies for glioblastoma, Expert Opinion on Biological Therapy. 2020.  
A combination of Ad-Tk/Flt3L is administered intratumorally. The prodrug, GCV, is 
administered via intraperitoneal injection. TK converts GCV into a toxic metabolite resulting 
in tumor cell death and release of damage associated molecules, such as HMGB1 and tumor 
antigens. Flt3L recruits dendritic cells into the tumor microenvironment where they take up 
tumor antigens released by dying tumor cells and present them to T cells via MHC complexes.  
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Chapter 2 : Generation of Mouse Models of Brainstem Glioma4 
Abstract 
Diffuse intrinsic pontine glioma (DIPG) is a brain tumor most commonly diagnosed in 
children of median age 6-7 and the prognosis is very poor. Information from genomic studies of 
autopsy and biopsy tissue has revealed the presence of recurrent activating mutations in ACVR1 
and dominant negative K27M mutations in the genes encoding histone H3 variants, H3.3 and 
H3.1. We developed genetically engineered immunocompetent mouse models to assess the role 
of ACVR1 G328V and the commonly co-expressed H3.1 K27M on DIPG pathogenesis using the 
Sleeping Beauty (SB) transposase system to target neural stem cells in the subventricular zone. 
We observed that ACVR1 G328V enhanced median survival, while the H3.1 K27M mutation 
did not significantly affect median survival on its own. Histological analysis of ACVR1 G328V 
mutant tumors displayed increased downstream signaling of bone morphogenetic pathway 
(BMP) as demonstrated by increased phospho-smad1/5 levels. We also demonstrated that the 
H3.1 K27M mutant tumors had decreased H3K27me3 levels. Additionally, transcriptome 
analysis of mutant ACVR1 neurospheres (NS) identified an increase in the transforming growth 
factor beta (TGF-β) signaling pathway and the regulation of cell differentiation. These data 
indicate that we are able to use the SB transposase system to develop in vivo and in vitro models 
 
4 Portions of this chapter have been submitted for publication in Clinical Cancer Research in collaboration with the 
following co-authors: Padma Kadiyala, Felipe J. Nunez, Stephen Carney, Fernando Nunez, Jessica C. Gauss, Ramya 
Ravindran, Sheeba Pawar, Marta Edwards, Pedro R. Lowenstein, and Maria G. Castro.  
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of relevant DIPG mutations. We also demonstrate that tumors can be induced in the brainstem 
and that we can generate transplantable models which allow for rapid testing of novel 
therapeutics.  
Introduction 
Diffuse Intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor 
for which there is no current treatment. Consequently, the percent of children who survive for 
longer than two years is less than ten percent. The most frequent DIPG mutations affect the N-
terminal tail of histone H3.3 and histone H3.1 and result in the change of a lysine to methionine 
at residue 27 (1-3). It has been reported that the K27M mutation inhibits Enhancer Of Zeste 2 
(EZH2) histone methyltransferase activity causing a global hypomethylation of H3K27 (4). Post-
translational modifications regulate chromatin structure and transcription and are particularly 
important during normal development, stem cell maintenance and differentiation(5,6) . Thus, a 
mutation that affects histone modifications may have a profound impact on gene expression with 
oncogenic consequences.  
Recently it was described that the next most frequently mutated gene in DIPG is ACVR1 
(mutated in 24% of DIPG cases) (7-10). ACVR1 encodes a type 1 BMP receptor and the six 
mutations reported are believed to result in constitutive BMP pathway activation (7-10). BMPs 
play important roles in the development of neural stem cells (11). Spatial temporal regulation of 
the BMPs enables them to fulfill their multiple roles. During neurogenesis BMPs initially 
promote neural lineage commitment and inhibit oligodendrocyte commitment, while during 
gliogenesis BMPs promote astrocyte lineage commitment (11). Additionally, in adulthood BMP 
signaling is important for the maintenance and differentiation of neural stem cells in the 
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subventricular zone and subgranular zone (11). Interestingly, the mutations found in DIPG 
overlap with germline mutations in ACVR1 that cause the musculoskeletal disorder 
fibrodysplasia ossificans progressiva (FOP) and some patients with this disorder have been 
reported to have atypical neurological symptoms and white matter lesions (12). 
Mouse models are crucial to elucidate the mechanisms by which ACVR1 G328V and 
H3.1 K27M contribute to DIPG pathogenesis in order to develop targeted therapies against these 
mutations. We used the sleeping beauty (SB) transposase system to develop mouse models of 
DIPG. SB is a transposase that is able to recognize inverted repeats/direct repeats (IR/DR) sites 
on DNA transposons and carry out a cut and paste reaction to integrate transposon DNA into a 
host genome(13). The SB system can be utilized to generate endogenous tumors that resemble 
gliomas through delivery of DNA transposons that encode oncogenes and tumor suppressors (14-
18). We utilized the SB transposase system to introduce plasmids encoding the activating 
ACVR1 mutation and H3.1 K27M mutation in the context of upregulated NRAS and p53 
knockdown into neural stem cells in the subventricular zone. In our mouse model ACVR1 
G328V was associated with increased median survival while the H3.1 K27M mutation did not 
alter median survival independently of ACVR1. Transcriptome analysis of ACVR1 mutant NS 
identified an increase in the TGF-β signaling pathway and signaling pathways regulating the 
pluripotency of stem cells. We also show that the SB system can be utilized to deliver plasmid 
DNA into the fourth ventricle of postnatal day 1 mice to generate brainstem gliomas. 
Additionally, we demonstrate that tumor neurospheres derived from the SB generated tumors can 
be implanted into the pons of adult mice to rapidly develop immune competent transplantable 




All animal studies were conducted according to guidelines approved by the Institutional Animal 
Care and Use Committee at the University of Michigan. Animals were housed in an AAALAC 
accredited animal facility and had constant access to food and water; they were monitored daily 
for tumor burden. Males and females were used. The strain of mice utilized in the study was 
C57BL/6 (Jackson Laboratory, 000664). A murine model of glioma was generated by employing 
the SB transposon system to integrate plasmid DNA into the genome of postnatal day 1 (P1) 
mouse pups. The plasmids utilized were as follows: (i) SB Transposase and luciferase (pT2C-
LucPGK-SB100X, henceforth referred to as SB/Luc) (ii) a short-hairpin against p53 (pT2-shp53-
GFP4, henceforth referred to as shp53) or shp53-NO-GFP (iii) a constitutively active mutant of 
NRAS (pT2CAG-NRASV12, henceforth referred to as NRAS) with or without (4) mutant 
ACVR1 G328V (pkt-ACVR1-G328V-IRES-Katushka; henceforth referred to as mACVR1) (1-
3). To create the mACVR1 plasmid we cloned pCMV5-ALK2-WT into pKT2-IRES-Katushka 
by blunt cloning. Then, we used the QuikChange II Site-Directed Mutagenesis Kit (Agilent, 
200523) to introduce (c.983G>T, p.Gly328Val) mutation into pKT2-ALK2-WT-IRES-Katushka, 
to generate pKT2-ACVR1-G328V-IRES-Katushka (Addgene plasmid #77437).  The resultant 
mACVR1 plasmid was confirmed by Sanger sequencing. SB/Luc, shp53 and NRAS plasmids 
were the generous gift of Dr. John Ohlfest (University of Minnesota, now deceased). The 
pCMV5-ALK2-WT plasmid was a generous gift from Jeff Wrana (Addgene plasmid #11741). 
All experiments were performed using post-natal day 1 (P1) or P2 wild-type C57BL/6 mice. The 
plasmid combinations injected were as follows: (1) (i) shp53 and NRAS (henceforth referred to 
as wt-ACVR1), (ii) shp53, NRAS, and ACVR1m. Mice were injected according to a previously 
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described protocol (2). Briefly, plasmids were mixed in mass ratios of 1:2:2:2:2 (20 µg plasmid 
in a total of 40 µL plasmid mixture) with in vivo-jetPEI® (Polyplus Transfection, 201-50G) (2.8 
µL per 40 µL plasmid mixture) and dextrose (5% total) and maintained at room temperature for 
at least 20 minutes prior to injection. Anesthesia was performed by placing the pup on ice for 2 
minutes and then on a neonatal stereotaxic stage cooled to 2-8°C to maintain anesthesia. The 
lateral ventricle (1.5 mm AP, 0.7 mm lateral, and 1.5 mm deep from the λ-suture) or fourth 
ventricle (3 mm posterior to the λ-suture and 3 mm deep) were targeted (4). Plasmid uptake and 
tumor development and progression was monitored as previously described (2,3). Animals were 
monitored daily for signs of morbidity (ataxia, impaired mobility, hunched posture, seizures, or 
scruffy fur). Symptomatic mice were transcardially perfused using Tyrode’s solution and fixed 
with 4% paraformaldehyde (PFA) (2,3,5).  
Immunohistochemistry (IHC) of paraffin embedded brains:  
Immunhistochemistry staining was performed as previously described (2,3). Briefly, after 
perfusion, mouse brains were harvested and post-fixed in 4% PFA then paraffin embedded. 
Tissue was sectioned using a rotary microtome. Heat mediated antigen retrieval was performed 
using either 1X Rodent Decloaker (Biocare Medical, RD 913) or citrate buffer (10 mM citric 
acid, 0.05% non-ionic detergent, pH 6) at 125°C for 30 seconds and at 90°C for 10s followed by 
quenching of endogenous peroxides using 0.3 % H2O2 for 30 minutes, and permeabilization 
with 0.025% Triton in TBS. Sections were blocked with 10% horse serum, 0.1% BSA in TBS) 
for 30 minutes and then incubated overnight at 4°C with primary antibody diluted in 0.1% BSA 
in TBS.  For 3,3′-Diaminobenzidine (DAB) staining the VECTASTAIN ABC HRP Kit (Vector 
Laboratories, PK-4000) was used. The Alexa Flour 488 Tyramide SuperBoost Kit (Thermo 
Fisher Scientific, NC1136352) was used for the phospho Smad1/Smad5/Smad8 (Ser463/465) 
 36 
(MilliporeSigma, AB3848-I) antibody. Bright-field images were obtained using Olympus MA 
BX53 microscope.  Flourescent images were obtained using confocal microscopy (Carl Zeiss: 
MIC-System). A list of all antibodies can be found on Appendix Table A1.  
Primary (NS): 
Mouse (NS) were generated from tumors that were developed using the SB system by injection 
of the following plasmid combinations (1) (i) shp53 and NRAS, or (ii) shp53, NRAS, and 
ACVR1m into the lateral ventricle (1.5 mm AP, 0.7 mm lateral, and 1.5 mm deep from the λ-
suture) following previously described protocols (2,3,5,6). When animals became symptomatic 
they were anesthetized then transcardially perfused with Tyrode’s solution. The brains were 
harvested and tumors were identified by fluorescence expression. The tumor was then extracted 
and placed in 300 µL of media in an Eppendorf tube. Then, the tumor was mechanically 
dissociated using a sterile plastic pestle that fit the walls of the Eppendorf tube. This was 
followed by incubation with 1 mL of a cell dissociation buffer (Accutase, 423201), then filtered 
through a 70 µm strainer and maintained in neural stem-cell media [DMEM/F12 with L-
Glutamine (Gibco, 11320-033), B-27 supplement (Gibco, 12587- 010), N-2 supplement (Gibco, 
17502-048), Penicillin-Streptomycin (Corning, Cellgro, 30-001-CI), and Normocin (InvivoGen, 
ant-nr-1)] at 37 °C, 5% CO2. hFGF and hEGF (Shenendoah Biotech,100-26, 100-146) were 
supplemented twice weekly at 1 µL (20 ng/µL each stock, 1000x stock) per 1 mL media. 
Primary mutant ACVR1 glioma NS were transduced with pLVX-OVA to generate mACVR1-
OVA NS and selected with 5 ug/mL puromycin (Sigma, P8833). pLVX-OVA was generated by 
cloning cytoplasmic ovalbumin from pCI-neo-cOVA (Addgene plasmid #25097) into pLVX-
mCherry-c1 (Takarabio, 632561) by Nde1 and EcoR1 directed cloning.  
Western blot: 
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NS were harvested and re-suspended in RIPA buffer (MilliporeSigma, R0278) with 1X of Halt™ 
Protease and Phosphatase Inhibitor Cocktail, EDTA-free (100X) (Thermo Scientific, 78441). 
The Pierce™ BCA Protein Assay Kit (Thermo Scientific, 23227) was used to measure protein 
concentration. 20 µg of protein extract were run on a 4-12% SDS-PAGE PAGE gel (Thermo 
Fisher Scientific, NuPAGE®, NP0322BOX) and transferred to nitrocellulose membranes (Bio-
Rad, 1620112). The membrane was probed with 1:500 of anti-phospho Smad1/Smad5/Smad8 
(Ser463/465) (MilliporeSigma, AB3848-I); 1:500 of anti-Smad1 antibody (Abcam, ab63356); 
1:500 of anti-Id1 (Biocheck, BCH-1/37-2); and 1:10,000 of β-actin antibody (MilliporeSigma, 
A1978). The secondary antibodies used were: 1:4000 of goat anti-rabbit (Dako, Agilent 
Technologies, P0448) and 1:20,000 of rabbit anti-mouse (Dako, Agilent Technologies, P0260 ). 
SuperSignal West Femto (Thermo Fisher Scientific,  34095) was used to for detection. 
 In vitro experiments with ACVR1 inhibitor: 
LDN-214117 is a specific ACVR1 inhibitor (7). To determine an effective concentration to 
inhibit ACVR1 signaling in our mouse NS we plated wild type or mutant ACVR1 cells in a T-25 
flak containing growth media supplemented with varying concentrations of LDN-214117 (0.03 
uM, 0.1 uM, 0.3 uM, 1 uM); Selleck Chemicals, S7147) or equivalent DMSO control. NS were 
incubated with inhibitor for 90 minutes and then cells were collected to assess phosphorylation 
of Smad1/5 and Id2 by western blot.  
Immunocytochemistry: 
SU-DIPG-VI and SU-DIPG-XX1 were obtained from Dr. Michelle Monje at Stanford University 
(Stanford, Ca) in accordance with an institutionally approved protocol at each institution. Cells 
were cultured in DMEM with 10% FBS. 1 X 105 cells per well were plated on glass slides 
coated with 2% gelatin. Cells were fixed with 4% PFA and permeabilized with PBS 1X plus 
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0.3% Tween. ICC was performed with 1:100 Id1 (Biocheck, BCH-1/195-14), pERK1/2 (Cell 
Signaling, 4370), pMEK1/2 (Santa Cruz, sc-7995-R), and 1:1000 goat anti-rabbit antibody, 
Alexa Flour 488 (Invitrogen, A -11034).  
RNA-seq analysis: 
RNA-seq analysis was performed in collaboration with the Bioinformatics Core at the University 
of Michigan. Read files from the University of Michigan Sequencing Core’s storage were 
downloaded and concatenated into a single fastq file for each sample. The quality of the raw 
reads data for each sample was assessed using FastQC [1] (version v0.11.3) to identify features 
of the data that may indicate quality problems (e.g. low quality scores, over-represented 
sequences, inappropriate GC content). The Tuxedo Suite software package was used for 
alignment, differential expression analysis, and post-analysis diagnostics. Briefly, we aligned 
reads to the reference genome including both mRNAs and lncRNAs (UCSC mm10) using 
TopHat (version 2.0.13) and Bowtie2 (version 2.2.1.). The default parameter settings for 
alignment were used, with the exception of: “--b2-very-sensitive” telling the software to spend 
extra time searching for valid alignments. We used FastQC for a second round of quality control 
(post-alignment), to ensure that only highquality data would be input to expression quantitation 
and differential expression analysis. We performed two different analysis techniques to specify 
differential expression: Tuxedo and DESeq2, using UCSC mm10.fa as the reference genome 
sequence. The volcano plot was produced using an R base script and encompasses all genes 
identified by our RNA-seq analysis. In order to identify significantly differentially expressed 
genes, we set a log2 fold change cut-off of 0.585 and –log10(FDR) greater than 1.3, where 
circles represent individual genes and colors as indicated (red-upregulated, green-downregulated) 
shown in Figure 3A. The data was analyzed using Advaita Bio’s iPathwayGuide 
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(https://www.advaitabio.com/ipathwayguide). This software analysis tool implements the 
‘Impact Analysis’ approach that takes into consideration the direction and type of all signals on a 
pathway, the position, role and type of every gene, etc., as described in (8-11). Gene Ontology 
(GO) enrichment analysis was performed using iPathwayGuide 
(http://www.advaitabio.com/ipathwayguide), displaying up- and down-regulated genes 
associated with the same GO and was shown in Figure 3C. GO Biological Processes, selected for 
relevance to phenotype, were plotted in a horizontal bar graph using graphpad shown in Figure 
3B. All 100 differentially expressed genes between wt-ACVR1 and mutant-ACVR1 NS were 
converted to excel with their corresponding gene names in uppercase in first column and log2-
fold change values in second column to create the rank file. This rank file is used as an input for 
gene set enrichment analysis (GSEA) pre-ranking on program downloaded from Broad Institute 
(http://software.broadinstitute.org/gsea/index.jsp). In addition, Broad Institute provides a gene 
set containing all GOs (c5.all.v7.0.symbols.gmt), which is also required to perform the pre-
ranking using 2000 permutations and gene set size range of 0 to 200. The enrichment map is 
generated using the Cytoscape platform and requires the rank and gmt files along with the 
positive/negative GSEA report files. Each node represents an individual GO, the size is reflective 
of the number of genes within that set, and the red color signifies positively regulated pathways. 
We set a pvalue cut off of 0.001 and FDR of 0.5. The stringency of our FDR was lowered due to 
encompass the underlying biological pathways differentially regulated by ACVR1 are shown in 
yellow in Figure 3D. The enrichment score plots for Regulation of BMP signaling Pathway and 
Regulation of Cell Differentiation are shown in Figure 3E and 3F respectively, which are images 
provided in the GSEA Pre-ranking report.  
Statistical analysis 
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All data were analyzed using GraphPad Prism version 8. Animals studies were performed with at 
least 3 animals per group. The statistical test used is indicated in each figure. A p ≤ 0.05 was 
considered significant.  
Results 
Mouse model of glioma expressing DIPG mutations induced by transforming neural 
progenitor cells using the SB transposase system 
To assess the impact of DIPG mutations in glioma pathogenesis we generated a 
genetically engineered mouse model of DIPG using the SB transposase system (14,15). We 
induced tumors by activation of the receptor tyrosine kinase (RTK)-RAS- phosphatidylinositol 
3-kinase (PI3K) pathway, which is upregulated in a large percentage of DIPGs, and through 
inactivation of TP53, also commonly mutated in DIPG (19-21). This was achieved through the 
delivery of the following plasmids: NRASV12, a short hair pin targeting tumor protein p53 
(TP53) (shP53), and SB transposase/firefly luciferase, with or without ACVR1G328V or H3.1 
K27M (Fig. 2.1 A) into the lateral ventricle of neonatal mice to target neural progenitor cells in 
the subventricular zone (Fig. 2.1 B). The four experimental groups were: (1) control (wt-ACVR1 
and wt- H3.1) [NRASV12 and shp53)], (2) mutant ACVR1 (mACVR1) [NRASV12, shp53, 
ACVR1G328V] (3) mutant H3.1 (H3.1 K27M) [NRASV12, shp53, HIST1H3BK27M], and (4) mutant 
ACVR1/H3.1 K27M) (NRASV12, shp53, ACVR1G328V, HIST1H3BK27M). The median survival 
(MS) of animals in the control group was 80 days post injection (dpi) (Fig. 2.1 C). mACVR1 
tumors (MS=119 dpi) had enhanced survival compared to control group [Mantel-Cox test; p = 
0.0029] (Fig. 2.1C). H3.1 K27M did not have an effect on survival compared to the control group 
[Mantel-Cox test; p = not significant (ns)] (Fig 2.1C). Surprisingly, tumors harboring 
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NRAS/shp53/ACVR1 G328V/H3.1 K27M had increased survival compared to both the control 
group (p<0.0001) and the mACVR1 group [Mantel-Cox test; p=0.0371] (Fig. 2.1C). Tumors 
induced with ACVR1 G328V had increased immunostaining of phopho-Smad1/5, a transducer 
of BMP signaling as compared to the NRAS/shP53 control (Fig. 2.2A). Furthermore, tumors 
induced with a plasmid combination including H3.1 K27M have decreased immunostaining of 
H3K27me3 as compared to the NRAS/shP53 control consistent with the global H3K27me3 loss 
observed in patients with H3K27M mutations (Fig. 2.2B).  
Characterization of mutant ACVR1 NS 
To assess the role of ACVR1 G328V we generated in vitro cultures from the mACVR1 
tumors. This was done by harvesting the brain once animals became symptomatic, excising the 
tumor which was identified by a Katushka fluorescent reporter, and dissociating the tumor to 
generate a single cell suspension. In culture the cells form 3D structures which we refer to as 
tumor NS (Fig. 2.3A). We characterized the in vitro tumor NS expressing mACVR1 and observed 
that they exhibited elevated levels of phospho-smad1/5 (Fig. 2.3B) and elevated levels of Id1 (Fig. 
2.3B). To test the effect of a specific inhibitor of ACVR1, LDN-214117, on phospho-Smad1/5 
signaling we treated mACVR1 NS with increasing concentrations of LDN-214117. We observed 
decreased levels of phospho-Smad1/5 and Id2, while the levels of total Smad1 remain unchanged 
(Fig. 2.3C). These results indicate that ACVR1 G328V activates the BMP signaling pathway in 
mACVR1 NS.  
To identify genes regulated by mACVR1 we performed RNAseq analysis on mACVR1 
and wt-ACVR1 NS and identified genes that were differentially regulated (1.5-fold; FDR-
corrected P < 0.05) (Figure 2.4A). The top three pathways that were impacted by ACVR1 G328V 
were focal adhesion (FDR corrected, p=0.004), the TGF-beta signaling pathway (FDR corrected, 
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p=0.004), and signaling pathways regulating pluripotency of stem cells (FDR corrected, 
p=0.009) (Figure 2.4B). Over expressed genes within the TGF-Beta pathway included ACVR1, 
and inhibitor of DNA binding genes Id1, Id2, and Id3 (Figure 2.4B). Gene set enrichment 
analysis (GSEA) suggests an enrichment in the response to BMP and the regulation of cell 
differentiation (Fig. 2.4C-E).  
Since one of the top signaling pathways involved the regulation of pluripotency in stem 
cells, we evaluated whether mACVR1 tumors express CD133, CD44, and Aldh1, stem cell 
markers. Intracranial wt-ACVR1 or mACVR1 tumors were established in the pons of adult mice 
using SB derived NS. The results demonstrate that mACVR1 tumors have increased expression 
of the cancer stem cell markers CD133 (p=0.0002) and CD44 (p=0.0112) (Fig. 2.5A). However, 
we did not observe differences in the expression of another cancer stem cell marker, i.e., 
Aldehyde dehydrogenase 1 family, member A1 (Aldh1) (Fig. 2.5A). We next investigated the 
tumor initiating potential of wt-ACVR1 and mACVR1 NS in vivo. With wt-ACVR1 NS, the 
minimum number of cells required to generate brainstem gliomas with 100% penetrance was 
1,000 cells, whereas, with mACVR1 NS it was possible to generate brainstem gliomas with 
100% penetrance using 500 cells (Fig. 2.5B). These results indicate that mACVR1 NS have a 
greater tumor initiating potential.  
Generation of gliomas in the brainstem using SB system  
To test if we could generate gliomas in a more physiologically relevant location we 
injected the SB plasmids into the fourth ventricle of postnatal day 1 mice which is near the pons 
(Fig. 2.6A). The median survival (MS) of mice in the mACVR1 group was 127 dpi while the 
median survival for the wt-ACVR1 group was MS=85 dpi (Fig. 2.6B). All tumors, regardless of 
ACVR1 mutation status, displayed high cellularity, nuclear atypia, invasive features, and grew in 
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the brainstem (Fig. 2.6C). Tumors expressed markers of glial cells including oligodendrocyte 
transcription factor 2 (Olig2) (Fig. 2.6D), glial fibrillary acidic protein (GFAP) (Fig. 2.6E), and 
the neural stem cell marker, Sox2 (Fig. 2.6F). Both the wt-ACVR1 group and mACVR1 tumors 
were positive for phosphorylated extracellular signal-regulated kinase (pERK) 1/2 (Fig. 2.6G). 
Additionally, we confirmed that tumors expressing mACVR1 exhibited activated Smad1/5/8 
transcription factors (Fig. 2.6H). This correlated with increased levels of the downstream 
canonical target gene, inhibitor of DNA binding 1 (Id1) (Fig. 2.6I). Since the SB tumors were 
generated from tumors induced by activation of the RTK-RAS-PI3K signaling pathway we 
checked if this pathway was activated in DIPG cultures. Indeed, we found that SU-DIPG VI (wt-
ACVR1) and SU-DIPG XX1 (mACVR1) cultures were positive for phosphorylated ERK1/2 
(Fig. 2.7A). We also observed that mACVR1 DIPG cells had increased levels of ID1 compared to 
WT ACVR1 DIPG cultures (Fig. 2.7B).  
Transplantable mouse model of brainstem glioma for pre-clinical testing 
To develop a model that can be utilized for rapid pre-clinical testing of DIPG therapies, 
we implanted mACVR1 NS into the pons of immune competent adult C57BL/6 mice (Fig. 2.8A). 
The median survival of mice bearing mACVR1 brainstem gliomas was 19 dpi (Fig. 2.8B), giving 
us an adequate therapeutic window. Mice bearing mACVR1 brainstem gliomas are positive for 
Ki67 (proliferating cells), GFAP (astrocyte marker), Vimentin (astrocytes and ependymal cells), 
Iba1 (microglia), but negative for MBP (a marker of mature oligodendrocytes) (Fig. 2.8C). The 
tumors are also positive for pERK1/2 and pMEK1/2 demonstrating activation of the RTK-RAS-
PI3K signaling pathway (Fig. 2.8C). We also observed expression of Id1 a downstream target 
gene of BMP-Smad1/5 signaling (Fig. 2.8C). Therefore, tumors derived by intracranial 
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implantation of mACVR1 tumor NS maintain key features of the spontaneous tumors derived 
using the SB system and are amenable to pre-clinical therapeutic implementation. 
Discussion 
The development of molecularly and histologically accurate animal models is critical for 
the identification and testing of novel therapeutic targets. When we initiated our study there were 
no available models studying the biology of a subgroup of DIPG patients co-expressing ACVR1 
and H3.1 K27M mutations. Therefore, we utilized the SB transposase system to generate 
endogenous mouse models of ACVR1 G328V and H3.1 K27M DIPG. The SB system efficiently 
and reproducibly integrates plasmid DNA into the neural progenitor cells’ host chromosomal 
DNA of neonatal mice, allowing for the functional assessment of the role of candidate DIPG 
genes in promoting tumor progression (14,15,17,18). Additionally, tumors arise in an immune 
competent mouse. Although, H3.1 K27M and ACVR1 mutations are hypothesized to be 
potential tumorigenic drivers in DIPG, we were not able to generate tumors with mACVR1 
alone, H3.1-K27M alone, or a combination of mACVR1, H3.1-K27M, and activated PIK3CA. 
This is consistent with reports that mutations of ACVR1 were not sufficient to make Tp53 null 
mouse astrocytes tumorigenic, and that PDGF signaling was required to generate tumors with 
H3.3 K27M and Tp53 loss (10,22). For this reason, it was necessary to utilize additional 
tumorigenic drivers. We used NRAS, in combination with p53 knockdown, because it has been 
shown to be able to generate mouse models of glioblastoma that have histologically relevant 
features by activation of the RTK/RAS pathway, which is altered in 61.7% of DIPG cases 
(15,17-19). We developed gliomas in the cerebral hemispheres by injecting plasmids encoding 
NRASV12D, shp53, ACVR1 G328V and/ or H3.1 K27M into the lateral ventricles. Tumors 
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harboring the ACVR1 G328V mutation exhibited elevated phospho-Smad1/5 levels. We also 
observed that mutant H3.1 K27M tumors had decreased levels of H3k27me3, a phenotype of 
K27M mutations. Thus, our SB generated tumors exhibited the well documented phenotypes of 
the ACVR1 and H3.1 K27M mutations.  
Since DIPG tumors originate in the pons, it was important for us to be able to test if we 
could develop gliomas in the pons. To do this, we injected plasmids encoding NRASV12D, 
shp53, and ACVR1 G328V into the fourth ventricle and showed that it was possible to induce 
tumors in the brainstem. Both the lateral ventricle and brainstem models of ACVR1 G328V 
exhibited a significantly increased median survival compared with wt-ACVR1 tumors. This is in 
contrast with results from Hoeman C.M. and colleagues in which the authors found that in an 
RCAS model of DIPG, driven by p53 loss and PDDGF-A, ACVR1 R206H accelerated tumor 
growth, in the presence or absence of H3.1 K27M (23). One potential reason for the difference in 
survival observed between our models may lie in the specific amino acid substitution that was 
modelled. We used the ACVR1 G328V mutation since this mutation was reported to be the most 
common of the six recurrent ACVR1 mutations. Recently it was reported that only amino acid 
substitutions of ACVR1 at the G328 residue confer a significant increase in survival (24). Thus, 
our SB model of ACVR1 G328V is consistent with what is seen in patients with mutations of 
glycine at position 328.  
Transcriptional profiling of neurospheres expressing mACVR1 versus wt-ACVR1 
confirmed upregulation of the TGF-beta pathway in mACVR1 NS, and identify pathways 
regulating the pluripotency of stem cells to be increased by the ACVR1 mutation. Additionally, 
we observed that mACVR1 NS have increased levels of stemness markers CD133 and CD44 
after re-implantation and greater tumor initiation potential when compared to wt-ACVR1 NS. 
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Taken together, our data suggests mACVR1 regulates stemness and tumor initiation potential. 
Interestingly, clonal evolution analysis of a DIPG tumor found that the ACVR1 mutation was 
present along with the H3.1 K27M mutation in all tumor clones, in contrast to secondary 
mutations found only in some subclones, implicating mACVR1in DIPG tumor initiation (25). In 
addition, Hoeman C.M. and colleagues observed that ACVR1 R206H contributed to increased 
tumor incidence using the RCAS model driven by p53 loss and PDDGF-A, supporting our 
results that ACVR1 plays a role in tumor initiation (23).  
The SB model also enabled us to generate an intracranial model of brainstem glioma 
through implantation of tumor NS into the pons of adult C57BL/6 mice. This implantation model 
has an intact immune system, and short latency enabling it to be used for pre-clinical testing of 
immune-mediated strategies for DIPG. We implanted tumors with mACVR1 NS, however, it 
would be possible to generate tumor NS expressing other DIPG mutations in order to test the 
effect of specific DIPG mutations on the efficacy of a pre-clinical therapy.  
In conclusion, we demonstrate the amenability of the SB transposase to be used to 
develop genetically and histologically accurate models of DIPG. We generated models of 
ACVR1 G328V and H3.1 K27M, two genes mutated in DIPG. Uncovering the role of these 
mutations on DIPG tumorigenesis and disease progression could provide novel mechanistic 





Figure 2.1 DIPG mouse models induced in the lateral ventricle 
(A) Schematic representation of SB transposase and transposon plasmids used to develop 
gliomas with DIPG mutations in the lateral ventricle. Black arrows indicate position of inverted 
repeat and direct repeat (IR/DR) sequences which flank specific DNA sequences. (B) (i) 
neonatal mouse on stereotaxic frame. Lateral ventricle coordinates: 1.5 mm ventral and 0.8 mm 
lateral to the lambda, (ii) bioluminescence imaging at 1-day post injection (dpi) confirming the 
efficiency of the in vivo transfection.  (iii) bioluminescence imaging at endpoint stage showing 
a large tumor (iv) fluorescence image of a GFP fluorescent tumor. (C) Kaplan-Meier survival 
curves for mice bearing lateral ventricle gliomas induced with NRASV12/shp53 (n = 12), 
NRASV12/shp53/ ACVR1G328V (n = 13), NRASV12/shp53/ H3.1 K27M (n = 23), 





 Figure 2.2 Characterization of DIPG gliomas induced in the lateral ventricle  
(A) IHC staining for phospho-Smad1/5 (p-Smad1/5) protein in paraffin embedded SB brainstem 
tumor sections of the (1) control group, (2) mACVR1, (3)H3.1 K27M) and (4) mACVR1/ H3.1 
K27M. Scale bar is 20 µm. Arrows represent positive staining. (B) IHC staining for H3K27me3 
protein in paraffin embedded SB brainstem tumor sections of the (1) control group, (2) 
mACVR1, (3)H3.1 K27M) and (4) mACVR1/ H3.1 K27M. Scale bar is 20 µm. Tumors 
harboring the H3.1 K27M have decreased positive staining for H3K27me3 compared to the 







5 The schematic from Figure 2.3A has been previously published in: Mendez, F.M., Nunez, F.J., Zorilla-Veloz R.I., 
Lowenstein, P.R., and Castro, M.G. Native Chromatin Immunoprecipitation Using Murine Brain Tumor 
Neurospheres, Journal of Visual Experiments, 2018; Jan 29;(131). 
 
Figure 2.3 ACVR1 G328V activates the phosphor-Smad1/5 signaling pathway 
(A) A bright field and fluorescent image of a brain harvested from a mouse that reached the end 
point stage. The tumor area is delineated by the dotted line and is positive for the fluorescent 
reporter, Katushka. The tumor is then isolated and the tumor tissue is dissociated and cultured in 
vitro where tumor NS form. (B) WB assay was performed on three different clones of wt-ACVR1 
and mACVR1 NS to assess the protein level of phopho-Smad1/5, Smad1, and Id1, a downstream 
Smad1/5 regulated gene. ß-actin: loading control. C1, C2, C3 represent the clones of NS used. (C) 
WB assay was performed on mACVR1 NS treated with LDN-214117 (0.03-1uM) and blotted for 






Figure 2.4 ACVR1G328V upregulates genes involved in the TGF-ß /Smad signaling and 
pathways related to stem cell maintenance and focal adhesion 
 (A) Differential gene expression in mACVR1 tumors analyzed by RNA-seq. Volcano plot 
comparing differentially expressed genes in mACVR1 versus wt-ACVR1 mouse NS. The log 
10 (FDR corrected p-values); q-values were plotted against the log 2 (Fold Change: FC) in gene 
expression. Genes upregulated by ≥ 1.3 fold and with a FDR corrected p-value < 0.05 are 
depicted as red dots; genes that were downregulated by ≥1.3 fold and with a FDR corrected p-
value < 0.05 are depicted as green dots. (B) Differentially expressed pathway genes associated 
with mACVR1 in mACVR1 versus wt-ACVR1 mouse NS. Plot of the log (FC) of genes with 
an FDR corrected p-value < 0.05. (C) Pathway enrichment maps of DE genes in mACVR1 
versus wt-ACVR1 NS. Clusters of nodes depicted in red illustrate differentially upregulated 
pathways resulting from GSEA (P < 0.05; FDR < 0.5). The yellow highlighted nodes indicate 
up-regulated GO terms containing ACVR1. (D) GSEA enrichment plot of regulation of BMP 
signaling pathway genes identified by RNA-Seq analysis in mACVR1 versus wt-ACVR1 
mouse NS. (E) GSEA enrichment plot of regulation of cell differentiation genes identified by 




Figure 2.5 Increased expression of stem cell markers and greater tumor initiation 
potential in mACVR1 NS compared to WT ACVR1 NS 
(A) Levels of CD133, CD44, and Aldh1 in the tumor microenvironment of mice bearing wt-
ACVR1 or mACVR1 was assessed when animals displayed signs of tumor burden. 
Representative histograms display each marker’s expression (green = wt-ACVR1, red = 
mACVR1). MFI = mean fluorescence intensity; * p < 0.05; *** p < 0.001; unpaired t test. Bars 
represent mean ± standard error of the mean (SEM) (n = 3 biological replicates). (B-C) In vivo 
tumor initiation capacity. Kaplan-Meier survival curves for mice intracranially implanted with 





Figure 2.6 Generation of mouse brainstem glioma model using the SB transposase 
system. 
(A)Schematic representation of brainstem glioma model. (i) One day old pups were injected in 
the fourth ventricle (3 mm posterior to the λ-suture and 3 mm deep) with plasmid cocktail. (ii) 
Bioluminescence imaging at 1-day post injection (dpi) confirming the efficiency of the in vivo 
transfection. (iii) Brightfield image of brainstem tumor (iv) Fluorescence image of  brainstem 
tumor with GFP reporter protein. (B). Kaplan-Meier survival curve for genetically engineered 
mice bearing  brainstem gliomas induced with NRASV12/shp53;[control] (n = 15), 
NRASV12/shp53/ ACVR1G328V (n = 11),  (C) Hematoxylin and eosin stained paraffin 
embedded SB brainstem tumor sections (control and mACVR1). Scale bar in the upper panel 
images is 200 µm. Scale bar in the bottom panel images is 20 µm. (D-I) Immunohistochemistry 
(IHC) staining for: (D) Olig2, an oligodendrocyte marker (scale bar in the upper panel image 
is 200 µm, scale bar for the bottom panel images is 50 µm) (E) GFAP, an astrocyte marker 
(scale bar in the upper panel image is 200 µm, scale bar for the bottom panel images is 20 µm) 
(F) Sox2, a transcription factor that plays an important role in the maintenance of neural stem 
cells (scale bar in the upper panel image is 200 µm, scale bar for the bottom panel images is 50 
µm) (G) phosphorylated ERK-1/2 protein (pERK1/2) (scale bar in the upper panel image is 200 
µm, scale bar for the bottom panel images is 50 µm). 
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(H) phospho-Smad1/5 (scale bar in the upper panel image is 100 µm, scale bar for the bottom 
panel images is 50 µm, white arrows indicate positive expression) (I) Id1 (scale bar in the upper 
panel image is 100 µm, scale bar for the bottom panel images is 50 µm). 
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Figure 2.7 DIPG cells express pERK1/2 and ID1 
Immunocytochemistry (ICC) staining for (A) pERK1/2 and (B) ID1 on human DIPG cells: SU-






Figure 2.8 Transplantable model of DIPG 
(A) Schematic of experimental design showing assessment of survival and histology in mice 
bearing mACVR1 brainstem gliomas. (B) Kaplan-Meier survival curve of mice bearing 
mACVR1 intracranial gliomas. MS = median survival. (C)Paraffin embedded mACVR1 tumor 
sections were stained with Hematoxylin and Eosin (H&E), Ki67 (proliferating cells), GFAP 
(astrocytes), MBP (myelin sheaths and oligodendrocytes), Vimentin (ependymal cells and 
astrocytes), Iba1 (microglia), pERK1/2, pMEK1/2, or Id1. Scale bar = 200 µm for the H&E. 
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Chapter 3 : Efficacy of Immune Stimulatory Gene Therapy in 
Mouse Models of Brainstem Glioma6 
Abstract 
Diffuse intrinsic pontine glioma (DIPG) bears a dismal prognosis. Mutant ACVR1 (mACVR1) 
neurospheres (NS) were implanted into the pons of immune competent mice to test the 
therapeutic efficacy and toxicity of immune stimulatory gene therapy using adenoviruses 
expressing thymidine kinase (TK) and fms-like tyrosine kinase 3 ligand (Flt3L). mACVR1 NS 
expressing the surrogate tumor antigen ovalbumin were generated to investigate if TK/Flt3L 
treatment induces the recruitment of tumor-antigen specific T cells to the tumor 
microenvironment (TME). Adenoviral delivery of TK/Flt3L in mice bearing brainstem gliomas 
resulted in anti-tumor immunity, recruitment of anti-tumor specific T cells to the TME and 
increased median survival. This study provides insights into the phenotype and function of the 
tumor immune microenvironment in a mouse model of brainstem glioma harboring mACVR1. 
Immune stimulatory gene therapy targeting the hosts’ anti-tumor immune response inhibits 
tumor progression and increases median survival of mice bearing mACVR1 tumors. 
 
6 Portions of this chapter have been submitted for publication in Clinical Cancer Research in collaboration with the 
following co-authors: Padma Kadiyala, Felipe J. Nunez, Stephen Carney, Fernando Nunez, Jessica C. Gauss, Ramya 
Ravindran, Sheeba Pawar, Marta Edwards, Pedro R. Lowenstein, and Maria G. Castro. 
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Introduction 
Brain and central nervous system tumors are the leading cause of cancer death in 
children(1). Diffuse intrinsic pontine glioma (DIPG) occurs mainly in children, and accounts for 
10-20% of pediatric brain tumors (2). DIPG originates in the pons and is highly invasive making 
surgical removal impossible. The median survival is 8-11 months, and has not improved in more 
than 40 years (3). Radiation can temporarily provide symptom relief and extend survival by a 
few months it can cause detrimental effects on developing brain (4,5). Thus, there is a critical 
need to identify an effective therapy for DIPG.  
It would be advantageous to harness the power of the immune system to elicit effective 
anti-tumor immunity in DIPG patients. Immune mediated treatment modalities have yielded 
promising clinical benefits in melanoma, non-small-cell lung cancer, renal cell cancer, and 
prostate cancer (6-9). We have also previously shown the efficacy of an immune stimulatory 
gene therapy approach in several rat and mouse models of adult glioblastoma (10,11). This 
approach has recently completed its Phase I Clinical Trial accrual for the treatment of adult 
patients with newly diagnosed glioblastoma multiforme (World Health Organization (WHO) 
grade IV (NCT01811992)). This immune-mediated gene therapy approach is based on 
adenoviral delivery of herpes simplex virus type 1-thymidine kinase (TK) and Fms-like tyrosine 
kinase 3 ligand (Flt3L). Upon administration of the prodrug, ganciclovir, proliferating tumor 
cells expressing TK undergo immunogenic cell death (10,11). Dying tumor cells, release 
damage-associated molecular patterns (DAMPs), such as high-mobility group B1 protein 
(HMGB1), calreticulin, and adenosine triphosphate (ATP) (10,12). Meanwhile, Flt3L elicits the 
recruitment of dendritic cells to the tumor microenvironment (10). HMGB1 released by dying 
tumor cells activates dendritic cells through Toll-like receptor 2 (TLR2) mediated signaling (10). 
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Activated dendritic cells pick up the tumor antigens and traffic to the draining lymph nodes, 
where they generate a specific anti-tumor cytotoxic T-cell response (10,13).  Herein, we aimed to 
test the efficacy of this immune stimulatory approach in an immunocompetent mouse model of 
mutant ACVR1 brainstem glioma.  
Treatment with TK/Flt3L immune stimulatory gene therapy significantly improved 
median survival compared to standard of care. The TK/Flt3L gene therapy induced a strong anti-
tumor cytotoxic immune response demonstrated by an increase in the frequency of tumor 
antigen-specific CD8 T cells in mice treated with TK/Flt3L therapy when compared to saline 
controls. Our results suggest that immune-mediated gene therapy could be a promising 
therapeutic approach for DIPG. 
Methods 
Implantable syngeneic murine brainstem glioma models: 
Female C57BL/6 mice between 6-8 weeks were used for all implantation experiments. 
Intracranial tumors were generated by stereotaxic injection of 1000 ACVR1m tumor NS into the 
pons using a 5 µl Hamilton syringe with a removable 33-gauge needle with the following 
coordinates: (0.8mm posterior; 1.00mm lateral to the λ-suture and 5mm deep). Animals were 
anesthetized, then the skin over the incision site was cut and retracted, and a burr hole was 
drilled into one side of the skull using a 0.45 mm drill bit corresponding to the pons coordinates. 
Tumor NS were delivered in a 2 µl volume after holding the needle in place for 2 minutes. Each 
injection was performed over the course of 7 minutes; the needle was left in place for an 
additional minute before being slowly withdrawn from the brain. 
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Intratumoral injection of adenoviral vectors and radiation treatment: 
We used first generation Ad.hCMV.hsFLT3L (Ad-Flt3L) + Ad.hCMV.TK (Ad-TK)(10,13). Five 
days post tumor implantation (dpi) mice were assigned to four treatment groups: (i) control 
group: empty Ad(Ad0)/saline); Ad0 was delivered intratumorally (i.t) and saline 
intraperitoneally (i.p.), (ii) gene therapy: Ad-TK(1×10^8 plaque-forming units (pfu)/Ad-
Flt3L(2×10^8 pfu of Ad-TK) /GCV; Ad-TK/Ad-Flt3Ldelivered i.t., ganciclovir (GCV) (Biotang; 
RG001-1g) was administered i.p. at 25 mg/kg/daily for 10d, starting 1d post-gene therapy, (iii) 
Standard of care (IR): Ad0/saline+IR; an overall dose of 20 Gy IR was administered (2 Gy/d for 
10d), and (iv) Gene therapy + standard of care: Ad-TK/Ad-Flt3L/GCV+IR. Intratumoral 
injections of adenoviral vectors was delivered in μL volume in three locations to depths of 4.4, 
4.5, and 4.6 mm, at the coordinates detailed above.  Sample size was n = 5 for each treatment 
group. For the functional analysis of T cells in the tumor microenvironment (TME), 8 days post 
tumor implantation mice were assigned to either the control group or the gene therapy group 
detailed above. Sample size was n = 3; where per sample it was necessary to pool tumor tissue 
from three mice for the control and five mice for the gene therapy group due to the size of the 
tumor.  
Flow cytometry: 
For flow cytometry experiments were performed using protocols described before (10,11,13).  
Flow data were acquired on a FACSAria flow cytometer (BD Biosciences) and analyzed using 
Flow Jo version 10 (Treestar). Prior to staining cells with antibodies, live/dead staining was 
carried out using fixable viability dye (eBioscience). Then, cells were resuspended in PBS 
containing 2% fetal bovine serum (FBS) (flow buffer) and non-specific antibody binding was 
blocked with CD16/CD32 (Biolegend, 101335). All stains were carried out for 30 minutes at 4°C 
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with 3X flow buffer washes between live/dead staining, blocking, surface staining, cell fixation, 
intracellular staining and data acquisition. The fixation/ permeabilization staining kit (BD 
Biosciences, 554714) was used for all intracellular stains. Antibody information is included in 
supplementary table 1. For T cell functional analysis within the TME, the cells from the tumor 
mass were stained with anti-mouse CD45, CD3, CD8, and SIINFEKL-H2Kb-tetramer-PE. For 
IFNγ stains, single cell suspensions generated from the tumor mass were stimulated with 25 
ug/mL of mACVR1-OVA lysate for 24 hours in 10% FCS-containing media followed by 6 h 
incubation with Brefeldin and monensin. Cells were stained with CD3 and CD8 antibodies, 
followed by intracellular staining for IFNγ.  To assess tumor cell stemness tumor cell 
suspensions generated from wt-ACVR1 and mACVR1 implanted tumors were stained for 
CD133, CD44, and Aldh1.  
Assessment of damage associated molecule release: 
To assess for release of damage associated molecules after treatment with either radiation (3G) 
or Ad-TK (500 MOI)/GCV (25µM), 10,000 mACVR1 NS were plated on 6-well plates. The next 
day they were treated with Ad-TK (500 MOI) and/or radiation (3G). Following a 48 hour 
incubation they were treated with GCV (25 µM ). The following day they were stained with 
calreticulin or high mobility group box 1 (HMGB1) antibodies following flow cytometry 
protocols described above.  To assess ATP release, we used the ATP determination kit following 
manufacturer’s instructions (Invitrogen, A22066) to measure ATP levels in media after 48 hours 
of treatment. Media was used to generate the ATP standard curve. 
T cell Proliferation analysis: 
Splenocytes from 21 dpi mACVR1-OVA brainstem glioma-bearing mice treated with saline or 
gene therapy, as detailed above, were labeled with Carboxyfluorescein succinimidyl ester 
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(CFSE) per manufacturer’s instructions and cultured with 100 nM SIINFEKL peptide (Anaspec, 
60193-1; dissolved in H20 and stored in -80 °C) for 4 days. As a positive control we used 
splenocytes from Rag2 knockout/transgenic OT-I T cell receptor mice (Taconic, 2334) 
stimulated with SIINFEKL. As a negative control we used unstimulated splenocytes. Cells were 
then stained with CD3 and CD8, and T cell proliferation was assessed based on CFSE dye 
dilution. 
Cytotoxic T cell assay: 
Splenocytes from saline or gene therapy treated mice were incubated with mACVR1-OVA NS 
for 24 hours at the indicated ratios (1:1, 10:1, 20:1).  Lysis of tumor cells was assessed by using 
Annexin-V. (14,15). 
Complete blood count (CBC) and serum chemistry: 
Collected blood was transferred to EDTA tubes for CBC (RAM Scientific, 077058) or in serum 
separation tubes (Sarstedt, 41.1378.005). CBC and serum chemistry was performed by the In-
Vivo Animal Core (IVAC) at the University of Michigan. 
Neuropathological analysis: 
To assess the safety of vector delivery into the brainstem, non-tumor bearing animals were 
treated with Ad-TK/Ad-Flt3L gene therapy or saline. GCV was administered intraperitoneally 
one day later for 7 days. One day after the last dose of GCV was administered animals were 
euthanized and brains were harvested and processed for histology as detailed above. 
Hematoxylin and eosin (H&E) staining was performed to assess gross histopathological features 
(16). Immunohistochemistry staining for glial fibrillary acidic protein (GFAP) to mark 
 65 
astrocytes, myelin basic protein (MBP) to mark myelin sheaths and oligodendrocytes, and Iba1 
to mark microglial cells. 
Hematoxylin and eosin (H&E): 
Liver tissue sections (5 µm thick) from tumor bearing animals treated with saline, radiation, gene 
therapy, and gene therapy and radiation were stained with H&E (16).  
Statistical analysis 
All data were analyzed using GraphPad Prism version 8, or R (version 3.1.3). All animal studies 
were carried out with at least 3 animals per group (specified in each experiment). The statistical 
test used is indicated in each figure. A p ≤ 0.05 was considered significant.  
Results 
Mutant ACVR1 NS release DAMPs in vitro 
Due to the invasive nature of brainstem gliomas and their refractive response to current 
therapies we wanted to assess the efficacy of immune stimulatory TK/Flt3L gene therapy. The 
release of DAMPs is crucial for the success of TK/Flt3L mediated therapy, therefore, we first 
assessed whether mACVR1 NS released DAMPs in vitro after treatment with GCV alone, TK 
alone, or GCV+TK, with, or without 3 Gray (Gy) of irradiation (IR). We found that mACVR1 
NS treated with GCV+TK released increased levels of calreticulin (p<0.0001; Fig. 3.1), high 
mobility group box 1 protein (HMGB1) (p<0.0001; Fig. 3.1), and adenosine triphosphate (ATP) 
(p = 0.0071; Fig. 3.1). We also observed that the combination of GCV+TK with IR further 
increased the levels of calreticulin (p<0.0001; Fig. 3.1), HMGB1 (p=0.0375; Fig. 3.1), and the 
release of ATP (p = 0.0158; Fig. 3.1) by the mACVR1 NS.  
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Pre-clinical testing of immune stimulatory gene therapy 
Having established that mACVR1 NS release calreticulin, HMGB1, and ATP in vitro 
following treatment with either IR or TK+GCV, we next tested the efficacy of this treatment 
paradigm in vivo. Five days’ post intracranial tumor implantation into the pons (Fig. 3.2A), mice 
were assigned to four treatment groups as indicated in Figure 3.2. Our results demonstrate that 
Ad-TK/Ad-Flt3L therapy was more effective in prolonging the median survival (MS) of 
mACVR1 brainstem glioma bearing mice compared to animals receiving IR,(MS=36 days post 
implantation (dpi) for TK/Flt3L group vs. 23 dpi for IR group; p = 0.0014, Mantel-Cox test), or . 
animals receiving saline control treatment (MS=18dpi; p = 0.0015, Mantel-Cox test) (Fig. 3.2B). 
Combining standard of care with gene therapy led to an improved median survival (MS=37 dpi), 
but did not significantly affect the efficacy of Ad-TK/Ad-Flt3L therapy (Fig. 3.2B).  
Assessment of anti-brainstem glioma specific T cells 
We next aimed to investigate whether Ad-TK/Ad-Flt3L treatment recruits anti-brainstem 
glioma specific T cells into the tumor immune microenvironment (TME). To do this, we used the 
surrogate tumor antigen ovoalbumin (OVA)(13,17) expressing mACVR1 cells (mACVR1-OVA 
NS). We were able to quantify tumor specific CD8 T cells in the TME through the use of the 
SIINFEKL-H2Kb tetramer (Fig. 3.3A). We observed a 3.8-fold increase in the frequency of 
tumor specific CD8 T cells in the TME after treatment with Ad-TK/Ad-Flt3L gene therapy (p = 
0.0007; ***, Fig. 3.3B). To test the impact of Ad-TK/Ad-Flt3L gene therapy on the activation 
status of CD8 T cells in the TME, we stained effector T cells for the expression of IFNγ after re-
stimulating CD8 T cells isolated from the TME with mACVR1-OVA NS-lysate for 24 hrs. Our 
data show that IFNγ is increased 3.8 fold (p = 0.0038; **, Fig. 3.3C) in CD8 T cells from Ad-
TK/Ad-Flt3L gene therapy treated mice compared to saline controls. To test if Ad-TK/Ad-Flt3L 
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gene therapy affected antigen-specific T cell proliferation we labeled splenocytes with 5-(and 6)-
carboxyfluorescein diacetate succinimidyl ester (CFSE), and stimulated them with the OVA 
cognate SIINFEKL peptide. As a positive control we also stimulated splenic T cells from OT-1 
mice that have their TCR engineered to recognize the SIINKEKL peptide. Our results show that 
the percentage of T cells that proliferated in response to the SIINKEKL peptide was greater (1.7 
fold, p <  0.0001, Fig. 3.3D) in mice treated with Ad-TK/Ad-Flt3L gene therapy compared to the 
saline treated control group. Additionally, the cytotoxicity of T cells isolated from the spleen of 
animals treated with Ad-TK/Ad-Flt3L gene therapy was observed to be significantly higher (1.95 
fold, p = 0.004 at 20:1 ratio, Fig. 3.3E) when compared with the saline treated group indicating 
that gene therapy significantly enhanced the cytotoxic activity of splenic T cells. 
Histopathological analysis 
To evaluate any potential adverse effects of delivering gene therapy into the brainstem 
we performed a detailed histopathological analysis of brains from non-tumor bearing animals. 
After the animals were treated intracranially with Ad-TK/Ad-Flt3L, GCV was administered 
intraperitoneally one day after adenoviral injection for seven days. Brains were harvested for 
neuropathology analysis 24 hours after the last dose of GCV was administered. Architectural 
integrity was assessed by H&E staining and by immunohistochemistry using GFAP (astrocytes), 
MBP (myelin sheaths, oligodendrocytes) and Iba1 (microglia). No gross tissue abnormalities 
were observed in response to TK/Flt3L therapy compared to the saline controls (Fig. 3.4). There 
was also no change in GFAP or MBP expression in response to TK/Flt3L therapy indicating that 
the brain architecture was unaffected (Fig. 3.4). There was no increase in Iba1 expression in the 
animals treated with TK/Flt3L therapy indicating that gene therapy does not induce inflammation 
in normal brain tissue 8 days’ post treatment. (Fig. 3.4).   
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Assessment of systemic toxicity  
To assess potential systemic toxicity due to TK/Flt3L or IR treatment, we performed 
H&E staining on liver sections and complete hematological and serum biochemical analysis in 
tumor bearing animals from the saline, TK/Flt3L, and TK/Flt3L + IR treatment groups. The liver 
sections from all treatment groups had normal hepatocyte architecture and did not show signs of 
inflammation or necrosis (Fig. 3.5). The white blood cell counts were within normal range for 
the saline, TK/Flt3L, and TK/Flt3L + IR groups, but significantly decreased in the IR group in 
comparison to the saline treated group (p < 0.0001, Fig. 3.6). This is consistent with a study that 
found that whole brain radiation significantly decreased total white blood cell counts (18). Red 
blood cell, hemoglobin, hematocrit, platelet, lymphocyte, neutrophil, and monocyte counts were 
not significantly affected by TK/Flt3L or IR therapy (Fig. 3.6). We did not find any significant 
changes in important enzymes involved in liver (ALT, AST) and kidney (BUN) function as a 
result of TK /Flt3L or IR therapies (Fig. 3.6).  
Discussion 
DIPG remains an incurable tumor with a poor prognosis (19). The tumors originate in the 
pons and infiltrate into sensitive regions of the brainstem precluding surgical resection (20). 
Currently, the treatment option for children with DIPG is limited to radiation to provide 
palliative care (21). Although radiation can temporarily provide symptomatic relief and extend 
survival by a few months, it can cause detrimental effects on the developing brain (4,5). 
Therefore, there is a dire need for new therapeutic interventions. DIPG studies involving the 
development and implementation of novel therapies have utilized patient derived xenograft 
models, where human DIPG cells are implanted into the brain of immune deficient mice or rats 
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to establish intracranial tumors (22,23). One limitation with those models is that immune 
suppressed animals cannot be used to test immunotherapies or perform immune-related 
mechanistic studies. We developed an immune competent transplantable mouse model of DIPG 
harboring the ACVR1 G328V mutation (mACVR1), and this study focuses on the response of 
mACVR1 brainstem glioma tumors to immunotherapies.  
There has been significant progress in the field of cancer immunotherapy leading to 
improvements in overall survival in many types of solid tumors (6-8,24,25). Advances in 
immunotherapies include the development of immune therapies targeting immune checkpoints, 
vaccine approaches against tumor antigens or dendritic cell vaccines designed to stimulate the 
adaptive immune response, adoptive cell therapy, oncolytic viral therapy, and immune 
stimulatory gene therapy (25-27). This has led to a growing number of clinical trials testing 
immunotherapies in DIPG (27).  
In recent years, it has been established that activated immune cells are able to migrate and 
enter into the brain parenchyma, and that the brain has a functional lymphatic system that allows 
for transport of CNS-antigens to the draining lymph nodes (28,29). Thus, the brain is capable of 
mounting T cell-mediated adaptive immune responses, but, since there are very low numbers of 
local professional antigen presenting cells within the normal brain, endogenous immune 
responses fail to trigger potent immune response against tumor antigens localized in the brain 
parenchyma (30,31).  
In adult glioblastoma (GBM) there is evidence of immune cell infiltration, but an 
immunosuppressive environment precludes effective anti-tumor immunity (26,32,33). GBM 
tumors establish an immunosuppressive environment by the release of immunosuppressive 
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cytokines, such as TGF-β and IL-10, by the recruitment or induction of immunosuppressive cells, 
such as regulatory T cells, myeloid-derived suppressor cells, or tumor associated macrophages, 
and by the expression of immune checkpoint receptor ligands (32-38). In comparison to adult 
GBM, initial studies of the tumor microenvironment in DIPG have found that there is a low number 
of immune infiltrates in human DIPG tumors and that they do not express inflammatory cytokines 
and chemokines (39,40). These data provide support for the use of an immune modulatory 
therapeutic strategy to enhance the recruitment of immune cells into the tumor, with the aim of 
mounting an effective anti-DIPG immune response. 
We have previously demonstrated that combined immune stimulatory gene therapy 
mediated through the delivery of adenoviruses encoding herpes simplex virus type 1 thymidine 
kinase (TK) and fms-like tyrosine kinase 3 ligand (Flt3L) leads to tumor regression and long 
term survival in several rodent models of glioblastoma (GBM) (10,11,41-43). This therapy is 
based on inducing tumor cell death though expression of suicide gene TK (44,45). Tumor 
antigens and damage-associated molecular pattern molecules (DAMPs), such as calreticulin, 
high mobility group box1 (HMGB1), and ATP, are released by dying tumor cells (12,46). The 
effectiveness of this combination therapy also relies on Flt3L to recruit dendritic cells into the 
tumor microenvironment, while the release of HMGB1 stimulates TLR2-dependent activation of 
dendritic cells (10,45,47). Activated dendritic cells can then transport antigens to the draining 
lymph nodes and induce tumor specific T cell responses (10,45). Initial results from the first in 
human Phase 1 clinical trial of combined adenoviral delivery of TK and Flt3L for the treatment 
of adult GBM are promising and report that the therapy was well tolerated (48). However, it has 
been established that the biology of DIPG and GBM is different (49). Therefore, it is necessary 
to assess the safety and efficacy of TK/Flt3L therapy in pre-clinical models of brainstem glioma. 
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Herein, we demonstrate that treatment with TK/Flt3L gene therapy in mice bearing mACVR1 
brainstem gliomas stimulates a strong anti-tumor cytotoxic immune response leading to a 
significant increase in survival (Fig. 3.2B). Treatment with TK/Flt3L increased the frequency of 
tumor-specific CD8 T cells (Fig. 3.3B) in the tumor microenvironment and increased toxicity as 
demonstrated by enhanced IFNγ production (Fig. 3.3C).  
Additionally, delivery of TK/Flt3L into the normal brainstem did not induce any local or 
systemic cytotoxicity. Hematoxylin and eosin staining and immunostaining for GFAP 
(astrocytes), MBP (myelin sheaths, oligodendrocytes), and Iba1 (activated macrophages and 
microglia) was used to assess local toxicity, and we observed no architectural abnormalities or 
overt inflammation as a result of TK/Flt3L therapy. Histological examination of hematoxylin and 
eosin stained liver tissue did not show signs of inflammation, necrosis, or alterations in normal 
hepatocyte structure. Hematological toxicity, assessed by complete blood count and serum 
chemistry analysis, indicated that TK/Flt3L therapy did not induce any toxicity as values from a 
TK/Flt3L treated group were not significantly altered when compared to saline treated animals. 
Our results are consistent with other pre-clinical studies that report the brainstem can tolerate 
adenoviral mediated immunotherapy (50,51). Results from a clinical trial (NCT03178032) 
utilizing adenoviral vector delivery of an oncolytic virus into the pons of DIPG patients will also 
shed light on the feasibility and toxicity of intratumoral adenoviral delivery into the brainstem 
(52).  
In conclusion, we provide compelling evidence that warrants further development of 
conditionally cytotoxic immune stimulatory gene therapy for the treatment of DIPG. We 
anticipate that in the clinic, this approach could also be used in combination with immune 
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checkpoint blockade to further enhance the therapeutic efficacy of the TK/Flt3L-mediated anti-





Figure 3.1 TK+GCV and radiation induce release DAMPs by mACVR1 NS 
mACVR1 NS were treated with TK (500 MOI) and/ or 3 Gray (Gy) ionizing radiation (IR), 
followed by GCV (25 µM) 24 hours later. Following a 48-hour incubation, levels of calreticulin 
and HMGB1 were assessed by flow cytometry, while levels of ATP release were assessed using 
a colorimetric assay. MFI = mean fluorescence intensity; * p < 0.05; **** p < 0.0001; two-way 




Figure 3.2 Efficacy of Immune-Stimulatory Gene Therapy 
(A) Experimental design showing mice bearing mACVR1 brainstem gliomas treated with 
saline or TK/FLT3L gene therapy on day 5 post tumor implantation, followed by intraperitoneal 
administration of GCV (25 mg/kg) on day 6-12. Radiation was administered at a dose of 
2Gy/Day for 5d for two weeks 5 days’ post tumor implantation; mice were monitored for 
survival. (B) Kaplan-Meier survival analysis for mice bearing mACVR1 tumors treated with 
saline (n = 5), IR (n = 6), TK+ GCV (n=5), or IR+TK+GCV (n=5). Data were analyzed using 





Figure 3.3 Immune stimulatory gene therapy induces tumor specific T-cell infiltration 
(A)Experimental design showing mice bearing mACVR1-OVA brainstem gliomas treated with 
saline or TK/FLT3L gene therapy on day 8 post implantation, followed by intraperitoneal 
administration of GCV (25 mg/kg) on day 9-15. (B) Tumor specific CD8 T cells within the 
TME of mACVR1-OVA tumors were analyzed by staining for SIINFEKL-Kb tetramer.  
 (C) Activation status of CD8 T cells within the TME was analyzed by staining for IFNγ after 
stimulation with tumor lysate. Representative flow plots for each group are displayed; *** p < 
0.001, ** p < 0.01; unpaired t test. Bars represent mean ± SEM (n = 3 biological replicates, 
where resected tumors from 3 animals were pooled for the control group and 5 animals were 
pooled for the gene therapy group). (D) Experimental design showing splenocytes from saline 
or TK/FLT3L treated mACVR1-OVA tumor bearing mice labeled with CFSE and then 
stimulated with 100 nM of SIINFEEKL peptide for four days in culture to assess CD8+ T cell 
proliferation. Histograms show representative CFSE staining from unstimulated splenocytes 
(negative control), OT-1 splenocytes undergoing rapid proliferation in response to SIINFEKL 
(positive control), and the effect of SIINFEKL-induced T cell proliferation on splenocytes from 
saline or TK/Flt3L treated mACVR1-OVA tumor bearing mice. Quantification of splenocytes 
undergoing T cell proliferation; **** p < 0.0001; oneway ANOVA followed by followed by 
Turkey’s multiple comparisons. Bars represent mean ± SEM (n = 3 biological replicates). (E) 
Splenocytes from saline or TK/Flt3L treated mice were incubated with mACVR1-OVA NS, 
for 24 hours at the indicated ratios. Lysis of tumor cells was assessed by using Annexin-V. 
mACVR1 NS undergoing apoptosis were identified as Annexin-V+/CD45- cells. Data were 
compared using unpaired t test; **** p < 0.0001; *** <0.001. Bars represent mean ± SEM (n 




Figure 3.4 Neuropathology Toxcicity Assessment 
Assessment of local toxicity of adenoviral delivery of TK/Flt3L into normal brainstem. Mice 
were injected in the pons with Ad-TK and Ad-Flt3L, or saline. GCV was administered 
intraperitoneally 24 h post vector delivery for 7 days. 24 h after the last dose of GCV was 
administered neuropathological analysis of the brain was assessed by H&E staining and 
immunostaining for GFAP (astrocytes), MBP (myelin sheaths, oligodendrocytes), and Iba1 





Figure 3.5 Liver Histology 
Mice bearing mACVR1 brainstem gliomas were treated with saline or TK/ FLT3L gene therapy 
on day 5 post tumor implantation, followed by intraperitoneal administration of GCV (25 
mg/kg) on days 6-12. Radiation was administered at a dose of 2 Gy/Day for 5d for two weeks 
5 days’ post tumor implantation. Livers were processed for histology on day 23. Bright field 
images of paraffin embedded liver sections stained with H&E of animals that were treated with 






Figure 3.6 Hematology and serum chemistry 
Mice bearing mACVR1 brainstem gliomas were treated with saline or TK/FLT3L gene therapy 
on day 5 post tumor implantation, followed by intraperitoneal administration of GCV (25 
mg/kg) on days 6-12. Radiation was administered at a dose of 2 Gy/Day for 5d for two weeks 
5 days’ post tumor implantation. Blood and serum samples were drawn on day 23 to assess 
clinical parameters. (A) White blood cell (WBC), (B) red blood cell (RBC), (C) hemoglobin, 
(D) hematocrit, (E) Platelet (PLT), (F) Lymphocytes, (G) Neurotrophils (Neu), (H) Monocytes, 
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Chapter 4: Summary and Conclusions 
Summary 
The work presented in this dissertation demonstrates the feasibility of generating mouse models 
which recapitulate the histopathological features of diffuse intrinsic pontine glioma (DIPG) using 
the Sleeping Beauty (SB) transposon system. The SB system enabled us to generate mouse 
models of brainstem glioma harboring ACVR1 G328V and H3.1 K27M, two prevalent DIPG 
mutations, in order to investigate their role in DIPG tumorigenesis. We also developed a 
transplantable model in the adult pons by implantation of tumor neurospheres expressing 
ACVR1 G328V. The development of this syngeneic model with an intact immune system 
allowed us to investigate the use of Thymidine Kinase (TK)/Fms-like tyrosine kinase 3 ligand 
(Flt3L) immune stimulatory therapy for DIPG. Here, I summarize the main conclusions of my 
thesis work and discuss their translational relevance. 
Challenges in the treatment of DIPG 
Diffuse intrinsic pontine glioma (DIPG) is a pediatric brainstem tumor with poor 
survival.  Surgical removal is not possible due to the sensitive location and diffusive nature of 
DIPG.  Biopsies are not necessary for diagnosis, so they are not routinely performed. This has 
hampered the ability to study the biology of this tumor and develop effective therapies.  Within 
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the past decade, collaborations between scientists, clinicians, and clinician scientists within the 
pediatric neuro-oncology community have led to the discovery of unique mutations driving 
DIPG, reviewed in chapter one of this thesis (1).  This was followed by the development of cell 
lines and in vivo xenograft models derived from tissue acquired at time of autopsy or biopsy 
material of DIPG patients (2). Xenograft models are valuable because they have standardized 
growth rates, times of death, and tumor localization, however, studies must be performed in 
immunocompromised mice which limits the ability to study the efficacy of immunotherapies (3). 
To overcome this limitation, we developed a genetically engineered animal model of brainstem 
glioma expressing DIPG mutations, as described in chapter two of this thesis. This enabled us to 
assess the role of individual mutations in DIPG pathogenesis.  Despite an increased 
understanding of the biology of the tumor there are still no effective therapies for the treatment 
of DIPG. Conventional chemotherapeutics and radiation have not shown an effective response 
therefore we investigated the efficacy of an immune stimulatory gene therapy, described in 
chapter 3 of this thesis.  
Using the Sleeping Beauty Transposase system to generate models of DIPG  
In 2014, a DIPG molecular subgroup co-expressing a mutation in activin receptor type I, 
(ACVR1), a bone morphogenetic (BMP) receptor, and the histone H3.1 K27M mutation (4,5) 
was identified. ACVR1 mutations and H3.1 K27M mutations are largely restricted to pontine 
gliomas, and DIPG patients harboring these mutations are characterized as having an earlier age 
of onset and longer overall survival, further highlighting the unique biology of this subgroup (4). 
The ACVR1 mutation activates the BMP-Smad1/5 signaling pathway while the H3.1 K27M 
mutation results in H3K27me3 hypomethylation. During development BMPs promote 
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astrogliogenesis while inhibiting oligodendrogliogenesis (6-8). BMP signaling is also implicated 
in supporting the maturation of oligodendrocytes (9). In adult glioblastoma, BMP-Smad1/5/8 
signaling induces differentiation of glioblastoma tumor initiating cells and decreases the in vivo 
tumor initiating ability of GBM cells (10). However, BMP-Smad1/5 signaling has also been 
shown to promote proliferation and migration in transformed astrocytes (11). Thus, it is unclear 
what role elevated Smad1/5 signaling plays in DIPG pathogenesis. To address this gap, we 
developed an animal model expressing the ACVR1 G328V and H3.1 K27M mutations using the 
Sleeping Beauty (SB) system (12).  
We first used the SB system to deliver plasmids encoding DIPG mutations into neural 
stem cells lining the lateral ventricles, a site where we had previously demonstrated that we 
could generate high grade gliomas. We demonstrated that mutant ACVR1 tumors had increased 
levels of phosphorylated Smad1/5/8 indicating upregulation of the BMP pathway. This was 
confirmed by RNA-seq analysis. We also identified a link between mutant ACVR1 and the 
regulation of stemness and increased tumor initiating potential.  Further, we confirmed that H3.1 
K27M mutant tumors exhibited global loss of H3K27me3. Our survival studies revealed that 
ACVR1 G328V increased median survival, while H31 K27M only enhanced median survival in 
the presence of the ACVR1 G328V, suggesting a potential cooperation.  
Once we had established a working model, we sought to improve it by initiating the 
tumors in the brainstem since DIPG arises from this anatomical location. We demonstrated that 
we could successfully induce tumors in the brainstem with histological features of DIPG through 
delivery of plasmid DNA into the fourth ventricle. The brainstem tumors were diffusive, spread 
into the cerebellum, and express markers of glioma cells.  Although, BMPs play an important 
role in mediating the differentiation of neural and glioma stem cells, we did not observe any 
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differences in the expression levels of Nestin or Olig2 in mutant or wt-ACVR1 tumors, 
indicating that mutant ACVR1 did not affect their differentiation state.  Mutant ACVR1 
enhanced median survival in our mouse model of brainstem glioma, reproducing the result we 
had observed in the lateral ventricle tumors. One caveat of this model is that at the time that 
animals begin to decline in health and present with neurological symptoms the tumors were very 
small and consequently there was a limited amount of tumor tissue. 
A limitation of the SB models of DIPG presented here is the requirement of NRAS as a 
tumorigenic driver since ACVR1 G328V and H3.1 K27M and were not sufficient to develop 
tumors when delivered into the postnatal pons. To date, no other genetically engineered models 
of DIPG have been generated postnatally that don’t require additional tumorigenic drivers. 
However, recently Pathania M. and colleagues demonstrated that the combination of H3.3 K27M 
and p53 knockdown could transform neural stem cells in the brainstem by delivery of PiggyBac 
DNA transposon plasmids at embryonic day 12.5, but it took 6-8 months for tumors to develop 
(13). Another group using in utero electroporation to transfect neural stem cells using PiggyBac 
DNA transposon plasmids was unable to generate tumors using H3.3 K27M and p53 knockdown 
at embryonic day 13.5 suggesting that the developmental window is more susceptible to 
transformation at embryonic day 12.5 (14). It would be interesting to see if at this developmental 
time point activating ACVR1 G328V and H3.1K27M mutations could be sufficient to transform 
neural stem cells in the brainstem.  
Immune stimulatory gene therapy is effective in a mouse model of DIPG 
The lack of immune competent mouse models of DIPG has limited the ability to study 
the efficacy of immunotherapeutic strategies for the treatment of DIPG. Therefore, one of the 
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aims of this dissertation was to test the efficacy of a therapeutic strategy developed by our 
laboratory that modulates the immune system to induce an anti-cancer response in our mouse 
model of DIPG (15-19). The immune mediated gene therapy approach relies on thymidine kinase 
(TK)-mediated killing of tumor cells where tumor cell death results in the release of antigens and 
damage associated molecular pathogen patterns, such as HMGB1, calreticulin, and ATP into the 
tumor microenvironment (15,20).  Previously, our lab has demonstrated that dying glioblastoma 
tumor cells release HMGB1 and activate dendritic cells recruited to the tumor microenvironment 
by adenoviral delivery of the adjuvant Flt3L(15). Activated dendritic cells then travel to the 
draining lymph nodes to initiate an anti-tumor T cell response. This therapeutic strategy has 
recently completed phase I clinical trial in patients with GBM with promising results (21).  Like 
glioblastoma tumors, DIPGs are also characterized by low immune cell infiltration (22,23). 
Therefore, we hypothesized that TK/Flt3L therapy would also be effective for the treatment of 
DIPG.  
In chapter 3 of this thesis, we show that intratumoral administration of TK/Flt3L therapy 
in mice bearing mACVR1 brainstem gliomas triggers a robust anti-tumor immune response that 
leads to enhanced median survival. We also established brainstem tumors expressing the 
surrogate tumor antigen ovalbumin and labeled antigen specific anti-brainstem glioma T cells 
using specific tetramers. Using these brainstem tumors, we demonstrated that TK/Flt3L therapy 
resulted in the recruitment of anti-brainstem glioma specific CD8 T cells into the tumor immune 
microenvironment.  Treatment with gene therapy also resulted in an increase in the frequency of 
tumor infiltrating CD8 T cells that release IFNγ, a cytokine released by activated CD8 T cells, 
was increased when exposed to specific tumor antigens.  Additionally, TK/Flt3L therapy also 
resulted in an increase in splenic CD8 T cell expansion and enhanced their cytotoxic activity. 
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Neurological examination post treatment with TK/Flt3L and GCV in a normal brain did not 
reveal any signs of treatment related neuro-toxicity, or overt inflammation.  We also did not 
observe any systemic toxicity as a result of TK/Flt3L therapy and GCV.  Overall, our results 
demonstrate that treatment with TK/Flt3L gene therapy achieves a robust anti-tumor efficacy and 
can be safely administered in the brainstem. I think future studies could investigate how different 
DIPG mutations impact the efficacy of immunotherapy. There is speculation, for example, that 
tumor cells with the H3.1 K27M mutation may have distinct effects on immune cell function 
compared with tumor cells with the H3.3 K27M mutation (22).  Since the K27M mutation 
affects 80% of DIPGs it will be important to understand the effects of this mutation on the 
efficacy of TK/Flt3L gene therapy (24-26).  
Translational Impact 
The work presented in this thesis has significant translational impact because radiation, the 
current standard of care for DIPG, does not improve the survival of DIPG patients and only 
provides palliative care. The dismal prognosis dictates the development of novel and safe 
approaches. In this thesis, I describe the development of a DIPG model bearing mutated ACVR1 
or H3.1 K27M, two mutations frequent in DIPG, using the SB transposon system in neonate 
mice.  We also demonstrated that TK/Flt3L therapy can be safely delivered to the brainstem in a 
transplantable model of DIPG and can generate an anti-tumor therapeutic immune response and 
extend the survival of mice bearing mACVR1 brainstem tumors. The development of 
immunocompetent mouse models was invaluable for the analysis of the immune stimulatory 
effect of TK/Flt3L therapy. The safety studies we performed indicate that TK/Flt3L gene therapy 
does not elicit immune-mediated toxicity or inflammation which is important because 
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inflammation in the brainstem could be life threatening. Overall, my thesis work provides 
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